To Amend § 1735 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735. Compounding in Licensed Pharmacies.

(a) “Compounding” means any of the following activities occurring in a licensed pharmacy, by or under the supervision of a licensed pharmacist, pursuant to a prescription:

1. Altering the dosage form or delivery system of a drug
2. Altering the strength of a drug
3. Combining components or active ingredients
4. Preparing a compounded drug product preparation from chemicals or bulk drug substances

(b) “Compounding” does not include reconstitution of a drug pursuant to a manufacturer’s direction(s) for oral, rectal, topical, or injectable administration, nor does it include the sole act of tablet splitting or crushing, capsule opening, or the addition of flavoring agent(s) to enhance palatability.

(c) “Compounding” does not include, except in small quantities under limited circumstances as justified by a specific, documented, medical need, preparation of a compounded drug product that is commercially available in the marketplace or that is essentially a copy of a drug product that is commercially available in the marketplace.

(d) The parameters and requirements stated by this Article 4.5 (Section 1735 et seq.) apply to all compounding practices. Additional parameters and requirements applicable solely to sterile injectable compounding are stated by Article 7 (Section 1751 et seq.).

To Amend § 1735.1 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.1. Compounding Definitions.

(a) “Ante-area” means an ISO Class 8 or better air quality where personnel hand hygiene and garbing procedures, staging of components, and other high-particulate-generating activities are performed, that is adjacent to the area designated for sterile compounding. It is a transition area that begins the systematic reduction of particles, prevents large fluctuations in air temperature and pressures in the buffer area or cleanroom, and maintains air flows from clean to dirty areas.

(b) “Beyond use date” means the date, or date and time, after which administration of a compounded drug preparation shall not begin, the preparation shall not be dispensed, and the preparation shall not be stored (other than for quarantine purposes).

(c) “Biological Safety Cabinet (BSC)” means a ventilated cabinet for compounded sterile drug preparations, having an open front with inward airflow for personnel protection, downward HEPA-filtered laminar airflow for product protection, and HEPA-filtered exhausted air for environmental protection. Where hazardous drugs are prepared, the exhaust air from the biological safety cabinet should be appropriately removed by properly designed external building ventilation.

(d) “Buffer area” means an area which maintains segregation from the adjacent ante-area by means of specific pressure differentials. The principle of displacement airflow shall be employed. This concept utilizes a low-pressure differential, high airflow principle. Using displacement airflow typically requires an air velocity of 40 ft per minute or more from the buffer area across the line of demarcation into the ante-area. The displacement concept may not be used to maintain buffer area requirements for sterile compounds which originate from any ingredient that was at any time non-sterile, regardless of intervening sterilization of the ingredient, for hazardous compounds, or for chemotherapy compounds.

(e) “Bulk drug substance” means any substance that, when used in the preparation of a compounded drug preparation, processing, or packaging of a drug, becomes an active
ingredient or a finished dosage form of the drug, but the term does not include any intermediate used in the synthesis of such substances.

(f)(e) “Cleanroom or clean area or buffer area” means a physically separate room or area with walls and doors with HEPA-filtered air that provides at least an ISO Class 7 or better air quality where the primary engineering control (PEC) is physically located.

1. For nonhazardous compounding a minimum differential positive pressure differential of 0.02- to 0.05-inch water column relative to all adjacent spaces is required.

2. For hazardous compounding at least 30 air changes per hour of HEPA-filtered supply air and a negative pressure of at least 0.01 inches of water column relative to all adjacent spaces is required.

(f) “Compounding Aseptic Containment Isolator (CACI)” means a unidirectional compounding aseptic isolator (CAI) designed to provide worker protection from exposure to undesirable levels of airborne drug throughout the compounding and material transfer processes and to provide an aseptic environment for compounding sterile preparations. Air exchange with the surrounding environment should not occur unless the air is first passed through a microbial retentive filter (HEPA minimum) system capable of containing airborne concentrations of the physical size and state of the drug being compounded. Where volatile hazardous drugs are prepared, the exhaust air from the isolator should be appropriately removed by properly designed external building ventilation.

(g) “Compounding Aseptic Isolator (CAI)” means a form of isolator specifically designed for non-hazardous compounding pharmaceutical ingredients or preparations while bathed with unidirectional air. It is designed to maintain an aseptic compounding environment within the isolator throughout the compounding and material transfer processes. Air exchange into the isolator from the surrounding environment should not occur unless the air has first passed through a microbial retentive filter (HEPA minimum) system capable of containing airborne concentrations of the physical size and state of the drug being compounded.

(i) “Controlled cold temperature” means 2 degrees to 8 degrees C (35.6 degrees to 46.4 degrees F).
(j) “Controlled freezer temperature” means -25 degrees to -10 degrees C (-13 degrees to 14 degrees F) or at a range otherwise specified by the pharmaceutical manufacturer(s) for that product.

(k) “Controlled room temperature” means 20 degrees to 25 degrees C (68 degrees to 77 degrees F).

(l) “Copy or essentially a copy” of a commercially available drug product includes all preparations that are comparable in active ingredients to commercially available drug products, except that it does not include any preparations in which there has been a change, made for an identified individual patient, which produces for that patient a clinically significant difference, as determined by a prescribing practitioner, between that compounded preparation and the comparable commercially available drug product.

(m) “Daily” means occurring every day that a pharmacy is operating, except when daily monitoring of refrigerator and freezer temperature are required, then daily means every 24 hours.

(n) Displacement airflow method: a concept which utilizes a low pressure differential, high airflow principle to maintain segregation from the adjacent ante-area by means of specific pressure differentials. This principle of displacement airflow shall require an air velocity of 40 ft per minute or more from the clean area across the line of demarcation into the ante area. The displacement concept may not be used to maintain clean area requirements for sterile compounds which originate from any ingredient that was at any time non-sterile, regardless of intervening sterilization of the ingredient, or for hazardous compounds.

(o) “Dosage unit” means a quantity sufficient for one administration to one patient, except that for self-administered ophthalmic drops, a quantity sufficient for 30 days or less shall be considered one dosage unit.

(p) “Equipment” means items that must be calibrated, maintained or periodically certified.

(q) “First air” means the air exiting the HEPA filter in a unidirectional air stream that is essentially particle free.

(r) “Gloved fingertip sampling” means a process whereby compounding personnel lightly
press each fingertip and thumb onto appropriate growth media, which are then incubated at a
temperature and for a time period conducive to multiplication of microorganisms, and then
examined for growth of microorganisms.

(r)(s) “Hazardous” means all anti-neoplastic agents identified by the National Institute for
Occupational Safety and Health (NIOSH) as meeting the criteria for a hazardous drug and any
other drugs, compounds, or materials identified as hazardous by the pharmacist-in-charge.

(b)(s)(t) “Integrity” means retention of potency until the expiration beyond use date noted
provided on the label, so long as the preparation is stored and handled according to the label
directions after it is dispensed.

(t)(u) “Lot” means one or more compounded drug preparation(s) prepared during one
uninterrupted continuous cycle of compounding from one or more common active
ingredient(s).

(u)(v) “Media-fill test” means a test that mimics compounding procedures using a growth-
based media to demonstrate the competency of compounding personnel in aseptic techniques. The
media fill test must mimic the most complex compounding procedures performed by the pharmacy
that aseptic techniques of compounding personnel or processes routinely employed do not
result in microbial contamination. To be valid, media-fill tests must be conducted on both the
most routine and the most challenging compounding procedures performed.

(v)(w) “Non-sterile-to-sterile batch” means any compounded drug preparation containing two
(2) or more dosage units with any ingredient that was at any time non-sterile, regardless of
intervening sterilization of that ingredient.

(w)(x) “Parenteral” means a preparation of drugs administered in a manner other than
through the digestive tract. This includes, but is not limited to, injection through one or more
layers of skin, administration into the eye, and by inhalation. It does not include topical,
sublingual, rectal or buccal routes of administration.

(x)(y) “Personal protective equipment” means clothing or devices that protect the employee
from exposure to drug products and minimize the contamination of compounded
preparations. These include shoe covers, head and facial hair covers, face masks, gowns, and
gloves.
“Potency” means active ingredient strength within +/- 10% (or the range specified in USP37-NF32, 37th Revision, Through 2nd Supplement Effective December 1, 2014) of the labeled amount. Sterile injectable products compounded solely from commercially manufactured sterile pharmaceutical products in a health care facility licensed under section 1250 of the Health and Safety Code are exempt from this definition. For those exempt, the range may be calculated and defined in the master formula.

“Preparation” means a drug or nutrient compounded in a licensed pharmacy; the preparation may or may not be sterile.

"Prescriber's office" or "prescriber office" means an office or suite of offices in which a prescriber regularly sees patients for outpatient diagnosis and treatment. This definition does not include any hospital, pharmacy, or other facility, whether or not separately licensed, that may be affiliated with, adjacent to, or co-owned by, the prescriber’s practice environment.

“Primary Engineering Control (PEC)” means a device that provides an ISO Class 5 or better environment through the use of unidirectional HEPA-filtered first air for the exposure of critical sites when compounding sterile preparations. Examples of PEC devices include, but are not limited to, laminar airflow workbenches, biological safety cabinets, sterile compounding automated robots, compounding aseptic isolators, and compounding aseptic containment isolators.

“Process validation” means demonstrating that when a process is repeated within specified limits, the process will consistently produce preparations complying with predetermined requirements. If any aspect of the process is changed, the process would need to be revalidated.

“Product” means a commercially manufactured drug or nutrient evaluated for safety and efficacy by the FDA.

“Quality” means the absence of harmful levels of contaminants, including filth, putrid, or decomposed substances, and the absence of active ingredients other than those listed on the label, and the absence of inactive ingredients other than those listed on the master formula record document.

“Segregated sterile compounding area” means a designated space for sterile-to-sterile
compounding where a PEC is located within either a demarcated area (at least three foot perimeter) or in a separate room. Such area or room shall not contain and shall be void of activities and materials that are extraneous to sterile compounding. The segregated sterile compounding area shall not be in a location that has unsealed windows or doors that connect to the outdoors, in a location with high traffic flow, or in a location that is adjacent to construction sites, warehouses, or food preparation. The segregated sterile compounding area shall not have a sink, other than an emergency eye-washing station, located within three feet of a PEC. The segregated sterile compounding area shall be restricted to preparing non-hazardous sterile-to-sterile compounded preparations.

1. The BUD of a sterile drug preparation made in a segregated sterile compounding area is limited to 12 hours or less as defined by section 1751.8(d).

2. When the PEC in the segregated sterile compounding area is a CAI or a CACI and the documentation provided by the manufacturer shows it meeting the requirements listed in section 1751.4(f)(1)-(3), the assigned BUD shall comply with section 1751.8(a)-(b).

(e)(ag) “Strength” means amount of active ingredient per unit of a compounded drug product preparation.


To Amend § 1735.2 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.2. Compounding Limitations and Requirements; Self-Assessment.

(a) Except as specified in (b) and (c), no drug product preparation shall be compounded prior to receipt by a pharmacy of a valid prescription for an individual patient where the prescriber has approved use of a compounded drug product preparation either orally or in writing. Where approval is given orally, that approval shall be noted on the prescription prior to compounding. (b) A pharmacy may prepare and store a limited quantity of a compounded drug product preparation in advance of receipt of a patient-specific prescription where and
solely in such quantity as is necessary to ensure continuity of care for an identified population of patients of the pharmacy based on a documented history of prescriptions for that patient population.

(c) A “reasonable quantity” as used in that may be furnished to a prescriber for office use by the prescriber as authorized by Business and Professions Code section 4052, subdivision (a)(1), means that amount of compounded drug product preparation that:

1. is ordered by the prescriber or the prescriber’s agent and paid for by the prescriber at a price that fairly reflects the fair market value of each drug preparation, using a purchase order or other documentation received by the pharmacy prior to furnishing that lists the number of patients seen or to be seen in the prescriber’s office for whom the drug is needed or anticipated, and the quantity for each patient that is sufficient for either office administration or application to patients in the prescriber’s office, or for distribution of not more than a 72-hour supply to the prescriber’s patients, as estimated by the prescriber; and

2. is delivered to the prescriber’s office and signed for by the prescriber or the prescriber’s agent; and

3. is sufficient for administration or application to patients solely in the prescriber’s office, or for furnishing of not more than a 72-hour supply for human medical practices, or a 120-hour supply for veterinary medical practices, solely to the prescriber’s own veterinary patients seen as part of regular treatment in the prescriber’s office, as fairly estimated by the prescriber and documented on the purchase order or other documentation submitted to the pharmacy prior to furnishing; and

4. That the pharmacist has a credible basis for concluding the quantity provided for office use is reasonable considering the intended use of the compounded medication and the nature of the prescriber’s practice; and

5. for With regard to any individual prescriber to whom the pharmacy furnishes, and with regard to all prescribers to whom the pharmacy furnishes, taken as a whole, is an amount which the pharmacy is capable of compounding in compliance with pharmaceutical standards for integrity, potency, quality and strength of the compounded drug product preparation; and

6. Does not exceed an amount the pharmacy can reasonably and safely compound.
(d) No pharmacy or pharmacist shall compound a drug preparation that:

1. Is classified by the FDA as demonstrably difficult to compound;
2. Appears on an FDA list of drugs that have been withdrawn or removed from the market because such drugs or components of such drugs have been found to be unsafe or not effective; or
3. Is a copy or essentially a copy of one or more commercially available drug products, unless that drug product appears on an ASHP (American Society of Health-System Pharmacists) or FDA list of drugs that are in short supply at the time of compounding and at the time of dispense, and the compounding of that drug preparation is justified by a specific, documented medical need made known to the pharmacist prior to compounding. The pharmacy shall retain a copy of the documentation of the shortage and the specific medical need in the pharmacy records for three years from the date of receipt of the documentation.

(d)(e) A drug product preparation shall not be compounded until the pharmacy has first prepared a written master formula record document that includes at least the following elements:

1. Active ingredients to be used.
2. Equipment to be used.
3. Expiration dating requirements. The maximum allowable beyond use date for the preparation, and the rationale or reference source justifying its determination.
4. Inactive ingredients to be used.
5. Process and/or procedure specific and essential compounding steps used to prepare the drug.
6. Quality reviews required at each step in preparation of the drug.
7. Post-compounding process or procedures required, if any.
8. Instructions for storage and handling of the compounded drug preparation.

(e)(f) Where a pharmacy does not routinely compound a particular drug product preparation, the master formula record for that product preparation may be recorded on the prescription document itself.

(f)(g) The pharmacist performing or supervising compounding is responsible for the integrity,
potency, quality, and labeled strength of a compounded drug product preparation until the beyond use date indicated on the label, so long as label instructions for storage and handling are followed after the preparation is dispensed.

(g)(h) All chemicals, bulk drug substances, drug products, and other components used for drug compounding shall be stored and used according to compendial and other applicable requirements to maintain their integrity, potency, quality, and labeled strength.

(h)(i) Every compounded drug product preparation shall be given an expiration beyond use date representing the date beyond which the compounded drug preparation should not be used, stored, transported or administered; and determined based on the professional judgment of the pharmacist performing or supervising the compounding, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used, stored, transported, or administration begun. This “beyond use date” of the compounded drug product preparation shall not exceed 180 days from preparation or the shortest expiration date of any component ingredient in the compounded drug product preparation, nor shall it exceed 180 days for non-aqueous formulations, 14 days for water-containing oral formulations, and 30 days for water-containing topical/dermal and mucosal liquid and semisolid formulations, from preparation unless a longer later date is supported by stability studies of finished drugs or compounded drug products preparations using the same identical components ingredient, specific and essential compounding steps, quality reviews, and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

(i)(j) The pharmacist performing or supervising compounding is responsible for the proper preparation, labeling, storage, and delivery of the compounded drug product preparation.

(j) Prior to allowing any drug product preparation to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment for compounding pharmacies developed by the board (Incorporated by reference is “Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment” Form 17M-39 Rev. 02/12.) as required by Section 1715 of Title 16, Division 17, of the California Code of Regulations. That form contains a first section applicable to all compounding, and a second section applicable to...
sterile injectable compounding. The first section must be completed by the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must be completed by the pharmacist-in-charge before any sterile injectable compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of each odd-numbered year, within 30 days of the start date of a new pharmacist-in-charge or change of location, and within 30 days of the issuance of a new pharmacy license. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

(k) Packages of ingredients, both active and inactive, that lack a supplier’s expiration date are subject to the following limitations:

1. such ingredients cannot be used for any non-sterile compounded drug preparation more than three (3) years after the date of receipt by the pharmacy, unless either appropriate and documented inspection or analytical testing indicates that the ingredient has retained its purity and quality for use in compounded drug preparations, considering the container in which it is packaged and the storage conditions, and

2. such ingredients cannot be used for any sterile compounded drug preparation more than one (1) year after the date of receipt by the pharmacy, unless either appropriate and documented inspection or analytical testing indicates that the ingredient has retained its purity and quality for use in compounded drug preparations, considering the container in which it is packaged and the storage conditions.

Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, and 4127, Business and Professions Code, Sections 1735, 1735.1, 1735.8, and 1751.1-1751.8 of Title 16, Division 17, of the California Code of Regulations.
To Amend § 1735.3 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.3. Records Recordkeeping of for Compounded Drug Products Preparations.
(a) For each compounded drug product preparation, the pharmacy records shall include:

(1) The master formula record document.
(2) The compounding document shall include the following:
   (2)(A) The date the drug product preparation was compounded.
   (2)(B) The identity of the pharmacy personnel who compounded the drug product preparation.
   (2)(C) The identity of the pharmacist reviewing the final drug product preparation.
   (2)(D) The quantity of each component ingredient used in compounding the drug product preparation.
   (2)(E) The manufacturer, expiration date and lot number of each component. If the manufacturer name is demonstrably unavailable, the name of the supplier may be substituted.
If the manufacturer does not supply an expiration date for any component, the records shall include the date of receipt of the component in the pharmacy, and the limitations of section 1735.2, subdivision (k) shall apply.
   (i) Exempt from the requirements in this paragraph (1735.3(a)(2)(E)) are sterile products preparations compounded on a one-time basis in a single lot for administration within seventy-two (72) hours to an inpatient in a health care facility licensed under section 1250 of the Health and Safety Code and stored in accordance with standards for “Redispensed CSPs” found in Chapter 797 of the United States Pharmacopeia – National Formulary (USP37-NF32) Through 2nd Supplement (35 37th Revision, Effective May December 1, 2012-2014), hereby incorporated by reference, to an inpatient in a health care facility licensed under section 1250 of the Health and Safety Code.
   (2)(F) A pharmacy-assigned reference or lot number for the compounded drug product preparation.
   (2)(G) The expiration beyond use date or beyond use date and time of the final compounded...
drug product preparation, expressed in the compounding record document in a standard date and time format.

(9)(H) The final quantity or amount of drug product preparation compounded for dispensing.

(b) Pharmacies shall maintain records of the proper acquisition, storage, and destruction of chemicals, bulk drug substances, drug products, and components used in compounding.

(c) Active ingredients shall be obtained from a supplier registered with the Food and Drug Administration (FDA). All other chemicals, bulk drug substances, and drug products, and components used to compound drug products preparations shall be obtained, whenever possible, from reliable FDA-registered suppliers. The pharmacy shall acquire and retain any available certificates of purity or analysis, either written in English or translated into English, for chemicals, bulk drug substances, and drug products, and components used in compounding. Certificates of purity or analysis are not required for drug products that are approved by the FDA. Any certificates of purity or analysis acquired by the pharmacy shall be matched to the corresponding product received.

(d) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created. If only recorded and stored electronically, on magnetic media, or in any other computerized form, the records shall be maintained as specified by Business and Professions Code section 4070 subsection (c).

Authority cited: Sections 4005, 4127, and 4169, Business and Professions Code.

Reference: Sections 4005, 4036, 4037, 4051, 4052, and 4127, Business and Professions Code.
To Amend § 1735.4 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.4. Labeling of Compounded Drug Products Preparations.

(a) In addition to the labeling information required under Business and Professions Code section 4076 and under California Code of Regulations section 1707.5, the label of a compounded drug product preparation shall contain the generic or brand name(s) of the principal all active ingredient(s).

(b) A statement that the drug has been compounded by the pharmacy shall be included on the container or on the receipt provided to the patient. Exempt from the requirements of this paragraph are those sterile drug preparations compounded within a health care facility solely for administration, by a licensed health care professional, to a patient of the facility. To be treated as such, the "health care facility" must be licensed under Health and Safety Code section 1250.

(c) Drug products preparations compounded into unit-dose containers that are too small or otherwise impractical for full compliance with subdivisions (a) and (b) shall be labeled with at least the name of the compounding pharmacy and dispensing pharmacy, if different, the name(s) of the active ingredient(s), concentration or strength, volume or weight of the preparation, pharmacy reference or lot number, and expiration beyond use date and shall not be subject to minimum font size requirements.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, 4076 and 4127, Business and Professions Code.
To Amend § 1735.5 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.5. Compounding Policies and Procedures.
(a) Any pharmacy engaged in compounding shall maintain a written policies and procedures manual for compounding that establishes procurement procedures, methodologies for the formulation and compounding of drugs, facilities and equipment cleaning, maintenance, operation, and other standard operating procedures related to compounding. Any material failure to follow the pharmacy’s written policies and procedures shall constitute a basis for disciplinary action.
(b) The policies and procedures manual shall be reviewed and such review shall be documented on an annual basis by the pharmacist-in-charge. The policies and procedures manual shall be updated whenever changes in policies and procedures processes are implemented.
(c) The policies and procedures manual shall include at least the following:
(1) Procedures for notifying staff assigned to compounding duties of any changes in processes or to the policies or procedures manual.
(2) Documentation of a written plan for recall of a dispensed compounded drug product preparation where subsequent verification information demonstrates the potential for adverse effects with continued use of a compounded drug product. The plan shall ensure that all affected doses can be accounted for during the recall.
(3) The procedures for maintaining, storing, calibrating, cleaning, and disinfecting equipment used in compounding, and for training on these procedures as part of the staff training and competency evaluation process.
(4) The procedures for evaluating, maintaining, certifying, cleaning, and disinfecting the facility (physical plant) used for compounding, and for training on these procedures as part of the staff training and competency evaluation process.
(45) Documentation of the methodology used to test validate integrity, potency, quality, and labeled strength of compounded drug products preparations. The methodology must be
appropriate to compounded drug preparations.

(56) Documentation of the methodology and rationale or reference source used to determine appropriate expiration beyond use dates for compounded drug products preparations.

(7) Dates and signatures reflecting all annual reviews of the policies and procedures manual by the pharmacist-in-charge.

(8) Dates and signatures accompanying any revisions to the policies and procedures manual approved by the pharmacist-in-charge.

(9) Policies and procedures for storage of compounded drug preparations in the pharmacy and daily documentation of all room, refrigerator, and freezer temperatures within the pharmacy.

(10) Policies and procedures regarding ensuring appropriate functioning of refrigeration devices, monitoring refrigeration device temperatures, and actions to take regarding any out of range temperature variations within the pharmacy.


To Amend § 1735.6 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.6. Compounding Facilities and Equipment.

(a) Any pharmacy engaged in compounding shall maintain written documentation regarding the facilities and equipment necessary for safe and accurate compounding of compounded drug products preparations. This shall include records of maintenance and cleaning of the facilities and equipment. Where applicable, this shall also include records of certification(s) of facilities or equipment.

(b) Any equipment used to compound drug products preparations shall be stored, used, and maintained, and cleaned in accordance with manufacturers' specifications.

(c) Any equipment that weighs, measures, or transfers ingredients used to compound drug
products preparations for which calibration or adjustment is appropriate shall be calibrated prior to use, on a schedule and by a method determined by the manufacturer’s specifications, to ensure accuracy. Documentation of each such calibration shall be recorded in writing in a form which is not alterable and these records of calibration shall be maintained and retained in the pharmacy.

(d) Any pharmacy engaged in any hazardous drug compounding shall maintain written documentation regarding appropriate cleaning of facilities and equipment to prevent cross-contamination with non-hazardous drugs.

(e) Hazardous drug compounding shall be completed in a physically separate room with the following requirements:

(1) Minimum of 12 air changes per hour; and

(2) Maintained at a negative pressure of at least 0.01 inches of water column relative to all adjacent spaces (rooms, above ceiling, and corridors); and

(3) All surfaces with the room shall be smooth, seamless, impervious, and non-shedding.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code.
Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.
To Amend § 1735.7 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1735.7. Training of Compounding Staff.

(a) A pharmacy engaged in compounding shall maintain documentation that demonstrates personnel involved in compounding have the skills and training required to properly and accurately perform their assigned responsibilities and documentation that personnel involved in compounding was trained in all aspects of policies and procedures. This training shall include but is not limited to support personnel (e.g. institutional environmental services, housekeeping), maintenance staff, supervising pharmacist and all others whose jobs are related to the sterile compounding process. Any pharmacy engaged in compounding shall maintain written documentation sufficient to demonstrate that pharmacy personnel have the
skills and training required to properly and accurately perform their assigned responsibilities relating to compounding. Additionally, documentation demonstrating that staff have been trained on all policies and procedures shall be maintained.

(b) The pharmacy shall develop and maintain an ongoing competency evaluation process for pharmacy personnel involved in compounding, and shall maintain documentation of any and all training related to compounding undertaken by pharmacy personnel.

(c) Pharmacy personnel assigned to compounding duties shall demonstrate knowledge about processes and procedures used in compounding prior to compounding any drug product preparation.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code.
Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

To Amend § 1735.8 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies and procedures, a written quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled strength of compounded drug products preparations.
(b) The quality assurance plan shall include written procedures for verification, monitoring, and review of the adequacy of the compounding processes and shall also include written documentation of review of those processes by qualified pharmacy personnel.
(c) The quality assurance plan shall include written standards for qualitative and quantitative analysis of compounded drug preparations to ensure integrity, potency, quality, and labeled strength, including the frequency of testing, analysis of compounded drug products preparations. All qualitative and quantitative analysis reports for compounded drug products preparations shall be retained by the pharmacy and collated maintained along with the
compounding record document and master formula document. The quality assurance plan shall include a schedule for routine testing and analysis of compounded drug preparations to ensure integrity, potency, quality, and labeled strength, on at least an annual basis.

(d) The quality assurance plan shall include a written procedure for scheduled action in the event any compounded drug product preparation is ever discovered to be below minimum standards for integrity, potency, quality, or labeled strength.

(e) The quality assurance plan shall include a written procedure for responding to out-of-range temperature variations within the pharmacy or within patient care areas of a hospital where furnished drug is returned for redispensing.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code.
Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

To Amend § 1751 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

Article 7. Sterile Injectable Compounding

1751. Sterile Injectable Compounding; Compounding Area; Self-Assessment.
(a) Any pharmacy engaged in compounding sterile injectable drug products preparations shall conform to the parameters and requirements stated by Article 4.5 (Section 1735 et seq.), applicable to all compounding, and shall also conform to the parameters and requirements stated by this Article 7 (Section 1751 et seq.), applicable solely to sterile injectable compounding.

(b) Any pharmacy compounding sterile injectable drug products preparations shall have a designated compounding area designated for the preparation of sterile injectable drug products preparations that is in a restricted location where traffic has no impact on the performance of the PEC(s). The buffer area or cleanroom, including the walls, ceilings, and floors, shall be constructed in accordance with Section 1250.4 of Title 24, Part 2, Chapter 12, of
the California Code of Regulations. The pharmacy shall be ventilated in a manner in accordance with Section 505.5 of Title 24, Part 4, Chapter 5 of the California Code of Regulations, which shall meet the following standards: The environments within the pharmacy shall meet the following standards:

(1) **Clean Room and Work Station Requirements**, shall be in accordance with Section 1250 of Title 24, Part 2, Chapter 12, of the California Code of Regulations.

(2) Walls, ceilings and floors shall be constructed in accordance with Section 1250 of Title 24, Part 2, Chapter 12, of the California Code of Regulations.

(3) Be ventilated in a manner in accordance with Section 505.12 of Title 24, Chapter 5 of the California Code of Regulations.

(4) Each ISO environment shall be certified annually at least every six months by a qualified technician who is familiar with the methods and procedures for certifying laminar air flow hoods and clean room requirements, in accordance with standards adopted by the United States General Services Administration in accordance with Section 1751.4. Certification records must be retained for at least 3 years in the pharmacy.

(5) The pharmacy shall be arranged in accordance with Section 1250 of Title 24, Part 2, Chapter 12, of the California Code of Regulations. Items related to the compounding of sterile injectable drug products preparations within the compounding area shall be stored in such a way as to maintain the integrity of an aseptic environment.

(6) A sink shall be included in accordance with Section 1250.4 of Title 24, Part 2, Chapter 12, of the California Code of Regulations. Sinks and drains shall not be present in any ISO Class 7 or better buffer area or cleanroom, nor in a segregated sterile compounding area within three feet of an ISO Class 5 or better PEC, with the exception of emergency eye-rinsing stations. A sink may be located in an ante-area.

(A) When the PEC in the segregated sterile compounding area is a CAI or CACI and the documentation provided by the manufacturer shows it meets the requirements listed in 1751.4(f)(1)-(3) they are exempt from the room requirement listed in 1751(b)(3)

(7) There shall be a refrigerator and, where appropriate, a freezer of sufficient capacity to meet the storage requirements for all material requiring refrigeration or freezing, and a
backup plan to ensure continuity of available compounded drug preparations in the event of a power outage.

(c) Any pharmacy compounding a sterile injectable drug product preparation from one or more non-sterile ingredients shall comply with Business and Professions Code section 4127.7.

Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, and 4127 and 4127.7, Business and Professions Code; Sections 1735, 1735.1-1735.8, and 1751.1-1751.8. of Title 16, Division 17, of the California Code of Regulations; and Section 18944, Health and Safety Code.

To Amend § 1751.1 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.1. Sterile Injectable Compounding Recordkeeping Requirements.

(a) Pharmacies compounding sterile injectable products for future use pursuant to section 1735.2 shall, in addition to those records required by section 1735.3, make and keep records indicating the name, lot number, amount, and date on which the products were provided to a prescriber.

(b) In addition to the records required by section 1735.3 and subdivision (a), any pharmacy engaged in any compounding of for sterile drug products preparations compounded from one or more non-sterile ingredients, shall make and keep maintain the following records must be made and kept by readily retrievable within the pharmacy:

(1) The Documents evidencing training and competency evaluations of employees in sterile product drug preparation policies and procedures.

(2) Results of hand hygiene and garbing assessments with integrated gloved fingertip testing.

(3) Results of assessments of personnel for aseptic techniques including results of media-fill tests and gloved fingertip testing performed in association with media-fill tests.

(4) Results of viable volumetric air and surface sampling.

(2)-(5) Documents indicating daily recordation documentation of room, R refrigerator, and
freezer temperatures appropriate for sterile compounded drug preparations consistent with the temperatures listed in section 1735.1 for:

(A) Controlled room temperature.

(B) Controlled cold temperature.

(C) Controlled freezer temperature.

(3)-(6) Certification(s) of the sterile compounding environment(s).

(7) Documents indicating daily documentation recodaration of air pressure differentials or air velocity measurements between all adjoining ISO rooms or areas, including those associated with compounding aseptic (containment) isolators, and air pressure differentials or air velocity measurements between all rooms or spaces with an immediate entry or opening to ISO rooms or areas.

(4)-(8) Other facility quality control logs records specific to the pharmacy’s policies and procedures (e.g., cleaning logs for facilities and equipment).

(5)-(9) Logs or other documentation inspections for expired or recalled pharmaceutical products or raw ingredients chemicals, bulk drug substances, drug products, or other ingredients.

(6)-(10) Preparation records including the master formula document work sheet, the preparation compounding document work sheet, and records of end-product evaluation testing and results.

(b) Pharmacies compounding sterile drug preparations for future use pursuant to section 1735.2 shall, in addition to those records required by section 1735.3, make and keep records indicating the name, lot number, and amount of any drug preparation compounded for future use, the date on which any preparation was provided to a prescriber, and the name, address, and license number of the prescriber.

(c) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created. If only recorded and stored electronically, on magnetic media, or in any other computerized form, the records shall be maintained as specified by Business and Professions Code section 4070 subsection (c).
To Amend § 1751.2 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.2. Sterile Injectable Compounding Labeling Requirements.

In addition to the labeling information required under Business and Professions Code section 4076 and California Code of Regulations sections 1707.5 and 1735.4, a pharmacy which compounds sterile injectable drug products shall include the following information on the labels for each such product:

(a) The telephone number of the pharmacy, except the telephone number is not required on the label for sterile injectable drug products dispensed for inpatients of a hospital pharmacy.

(b) Name (brand or generic) and concentration strength, volume, or weight of each active ingredient contained in the sterile injectable drug product.

(c) Instructions for storage and handling.

(d) All cytotoxic hazardous agents shall bear a special label which states “Chemotherapy - Dispose of Properly” or “Cytotoxic Hazardous – Dispose of Properly.”


To Amend § 1751.3 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:


(a) Any pharmacy engaged in compounding sterile drug preparations shall maintain a written policies and procedures manual for compounding. Any material failure to follow the
pharmacy’s written policies and procedures shall constitute a basis for disciplinary action. In addition to the elements required by section 1735.5, written policies and procedures regarding the following:

(1) Action levels for colony-forming units (CFUs) detected during viable surface sampling, glove fingertip, and viable air sampling.

(2) Airflow considerations and pressure differential monitoring.

(3) An environmental sampling plan and procedures specific to viable air, surface and gloved fingertip sampling as well as nonviable particle sampling.

(4) Cleaning and maintenance of ISO environments and segregated compounding areas.

(5) Compounded sterile drug preparation stability and beyond use dating.

(6) Compounding, filling, and labeling of sterile drug preparations.

(7) Daily and monthly cleaning and disinfection schedule for the controlled areas and any equipment in the controlled area as specified in section 1751.4.

(8) Facility management including certification and maintenance of controlled environments and related equipment.

(9) For compounding aseptic isolators and compounding aseptic containment isolators, documentation of the manufacturer’s recommended purge time.

(10) Hand hygiene and garbing.

(11) Labeling of the sterile compounded drug preparations based on the intended route of administration and recommended rate of administration.

(12) Media-fill testing procedure.

(13) Orientation, training, and competency evaluation of staff in all aspects of the preparation of sterile drug preparations including didactic training and knowledge/competency assessments that include at minimum: hand hygiene and garbing; decontamination (where applicable); cleaning and disinfection of controlled compounding areas; and proper aseptic technique.

(14) Preparing sterile compounded drug preparations from non-sterile components (if applicable). This shall include sterilization method suitability testing for each master formula document.
(15) Procedures for handling, compounding and disposal of hazardous agents. The written policies and procedures shall describe the pharmacy protocols for cleanups and spills in conformity with local health jurisdiction standards.

(16) Procedures for handling, compounding and disposal of infectious materials. The written policies and procedures shall describe the pharmacy protocols for cleanups and spills in conformity with local health jurisdiction standards.

(17) Proper use of equipment and supplies.

(18) Quality assurance program.

(19) Record keeping requirements.

(20) Temperature monitoring in compounding and controlled storage areas.

(21) The determination and approval by a pharmacist of ingredients and the compounding process for each preparation before compounding begins.

(22) Use of automated compounding devices (if applicable).

(23) Visual inspection and other final quality checks of sterile drug preparations.

(a) Any pharmacy engaged in compounding sterile injectable drug products shall maintain a written policies and procedures manual for compounding. Any material failure to follow the pharmacy’s written policies and procedures shall constitute a basis for disciplinary action, that includes, in addition to the elements required by section 1735.5, written policies and procedures regarding the following:

(1) Compounding, filling, and labeling of sterile injectable compounds.

(2) Labeling of the sterile injectable product compounded drug preparations based on the intended route of administration and recommended rate of administration.

(3) Proper use of equipment and supplies.

(4) Training of staff in the preparation of sterile injectable drug products. Hand hygiene and garbing.


(6) Quality assurance program.

(7) Record keeping requirements.

(8) Compounded sterile drug preparation stability and beyond use dating.
(9) Visual inspection and other final quality checks of sterile drug preparations.
(10) Use of automated compounding devices (if applicable).
(11) Preparing sterile compounded drug preparations from non-sterile components (if applicable). This shall include sterilization method suitability testing for each master formula document.
(12) Orientation, training, and competency evaluation of staff in all aspects of the preparation of sterile drug preparations including didactic training and knowledge/competency assessments that include at minimum: hand hygiene and garbing; decontamination (where applicable); cleaning and disinfection of controlled compounding areas; and proper aseptic technique.
(13) Airflow considerations and pressure differential monitoring.
(14) Cleaning and maintenance of ISO environments and segregated compounding areas.
(15) An environmental sampling plan and procedures specific to viable air, surface and gloved fingertip sampling as well as nonviable particle sampling.
(16) For compounding aseptic isolators and compounding aseptic containment isolators, documentation of the manufacturer’s recommended purge time.
(17) Temperature monitoring in compounding and controlled storage areas.
(18) Facility management including certification and maintenance of controlled environments and related equipment.
(19) Action levels for colony-forming units (CFUs) detected during viable surface testing, sampling, glove fingertip, and volumetric viable air sampling.
(b)(20) The determination and approval by a pharmacist of the ingredients and the compounding process for each preparation must be determined in writing before compounding begins and must be reviewed by a pharmacist.
(c)(21) Pharmacies compounding sterile injectable drug products preparations shall have written policies and procedures for the disposal of infectious materials and/or materials containing cytotoxic hazardous residues. Procedures for handling, compounding and disposal of hazardous agents. The written policies and procedures shall describe the pharmacy protocols for cleanups and spills in conformity with local health jurisdiction standards.
(22) Procedures for handling, compounding and disposal of infectious materials. The written policies and procedures shall describe the pharmacy protocols for cleanups and spills in conformity with local health jurisdiction standards.

(23) Daily and monthly cleaning and disinfection schedule for the controlled areas and any equipment in the controlled area as specified in section 1751.4.

(b) For lot compounding, the pharmacy shall maintain a written policies and procedures manual that includes, in addition to the elements required by section 1735.5 and 1751.3(a), written policies and procedures regarding the following:

(1) Use of master formulas documents and compounding documents work sheets.

(2) Appropriate documentation.

(3) Appropriate sterility and potency testing.

(c) For non-sterile-to-sterile batch compounding, the pharmacy shall maintain a written policies and procedures manual for compounding that includes, in addition to the elements required by section 1735.5 and 1751.3(a), written policies and procedures regarding the following:

(1) Sterilization methods and shall include sterilization method suitability testing for each master formula document.

(2) End-product evaluation, quantitative, and qualitative testing.

(d)(1) All written policies and procedures manuals and materials shall be immediately available to all personnel involved in these compounding activities and to board inspectors.

(d)(2)(e) All personnel involved must read the policies and procedures before compounding sterile injectable products drug preparations, and any additions, revisions, and deletions to the written policies and procedures must be communicated to all personnel involved in sterile compounding. This review must be documented by a signature and date.

(3) Policies and procedures must address at least the following:

(A) Competency evaluation.

(B) Storage and handling of products and supplies.

(C) Storage and delivery of final products.

(D) Process validation.
(E) Personnel access and movement of materials into and near the controlled area.

(F) Use and maintenance of environmental control devices used to create the critical direct compounding area for manipulation of sterile products (e.g., laminar-airflow workstations, biological safety cabinets, class 100 cleanrooms, and barrier isolator workstations).

(G) Regular cleaning schedule for the controlled areas and any equipment in the controlled area and the alternation of disinfectants. Pharmacies subject to an institutional infection control policy may follow that policy as it relates to cleaning schedules and the alternation of disinfectants in lieu of complying with this subdivision.

(H) Disposal of packaging materials, used syringes, containers, and needles to enhance sanitation and avoid accumulation in the controlled area.


To Amend § 1751.4 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.4. Facility and Equipment Standards for Sterile Injectable Compounding.

(a) No sterile injectable drug product preparation shall be compounded if it is known, or reasonably should be known, that the compounding environment fails to meet criteria specified in the pharmacy’s written policies and procedures for the safe compounding of sterile injectable drug products preparations.

(b) During the compounding of preparation of sterile injectable drug products preparations, access to the areas designated area or cleanroom for compounding must be limited to those individuals who are properly attired.

(c) All equipment used in the areas designated area or cleanroom for compounding must be made of a material that can be easily cleaned and disinfected.

(d) Cleaning and disinfecting surfaces in the ISO Class 5 PEC shall occur frequently, including:
Cleaning shall be done using a germicidal detergent and sterile water. The use of a sporicidal agent is required to be used at least monthly.

1. All ISO Class 5 surfaces, work table surfaces, carts, counters, and the cleanroom floor shall be cleaned at least daily. After each cleaning, disinfection using a suitable sterile agent shall occur on all ISO Class 5 surfaces, work table surfaces, carts, and counters.

2. Walls, ceilings, storage shelving, tables, stools, and all other items in the ISO Class 7 or ISO Class 8 environment shall be cleaned at least monthly.

3. Cleaning shall also occur after any unanticipated event that could increase the risk of contamination.

4. All cleaning materials, such as wipers, sponges, and mops, shall be non-shedding and dedicated to use in the cleanroom, or ante-area, and segregated sterile compounding areas and shall not be removed from these areas except for disposal.

5. Disinfection, using a suitable sterile agent, shall also occur on all surfaces in the ISO Class 5 PEC frequently (at least every 30 minutes), including:

   1. At the beginning of each shift;

   2. Before and after each lot;

   3. After each spill; and

   4. When surface contamination is known or suspected.

(d) Exterior workbench surfaces and other hard surfaces in the designated area, such as walls, floors, ceilings, shelves, tables, and stools, must be disinfected weekly and after any unanticipated event that could increase the risk of contamination. Counters, cleanable work surfaces and floors shall be cleaned with a germicidal detergent and water and disinfected with a suitable agent daily. Walls, ceilings, storage shelving, tables and stools shall be cleaned with a germicidal detergent and water and disinfected with a suitable agent monthly. Cleaning and disinfecting shall occur after any unanticipated event that could increase the risk of contamination.

(e)-(f) Pharmacies preparing sterile compounded preparations require the use of a PEC that provides ISO Class 5 air or better air quality. Certification and testing of primary and secondary engineering controls shall be performed no less than every six months and whenever the
device or area designated for compounding is relocated, altered or a service to the facility is performed that would impact the device or area. Certification must be completed by a qualified technician who is familiar with certification methods and procedures in accordance with CETA Certification Guide for Sterile Compounding Facilities (CAG-003-2006-11, Revised January 31, 2012). Certification records must be retained for at least 3 years. Unidirectional compounding aseptic isolators or compounding aseptic containment isolators may be used outside of an ISO Class 7 buffer area or cleanroom if the isolator meets the following criteria:

1. Particle counts sampled approximately 6-12 inches upstream of the critical exposure site shall maintain ISO Class 5 levels during compounding operations.
2. Not more than 3520 particles (0.5 um and larger) per cubic meter shall be counted during material transfer, with the particle counter probe located as near to the transfer door as possible without obstructing transfer.
3. Recovery time to achieve ISO Class 5 air quality shall be documented and internal procedures developed to ensure that adequate recovery time is allowed after material transfer before and during compounding operations.

Compounding aseptic isolators or compounding aseptic containment isolators that do not meet the requirements as outlined in this subdivision or are not located within an ISO Class 7 buffer area cleanroom may only be used to compound preparations that meet the criteria specified in accordance with subdivision (d) of Section 1751.8 of Title 16, Division 17, of the California Code of Regulations.

(g) Pharmacies preparing parenteral cytotoxic sterile hazardous agents shall do so in accordance with Section 505.125.1 of Title 24, Chapter 5, of the California Code of Regulations, requiring a laminar air flow hood negative pressure PEC. Additionally, each PEC used to compound hazardous agents shall be externally vented. The hood negative pressure PEC must be certified annually every six months by a qualified technician who is familiar with CETA Certification Guide for Sterile Compounding Facilities (CAG-003-2006-11, Revised January 31, 2012). The methods and procedures for certifying laminar air flow hoods and cleanroom requirements, in accordance with National Sanitation Foundation Standard 49 for Class II (Laminar Flow) Biohazard Cabinetry, as revised May, 1983 (available from the...
National Sanitation Foundation, 3475 Plymouth Road, P.O. Box 1468, Ann Arbor, Michigan 48106, phone number (313) 769-8010 or manufacturer’s specifications. Certification records must be retained for at least 3 years. Any drug preparation that is compounded in a PEC where hazardous drugs are prepared must be labeled as hazardous, regardless of whether the drug ingredients are considered hazardous.

(1) During the hazardous drug compounding that is performed in a compounding aseptic containment isolator, full hand hygiene and garbing must occur, complete with Garbing shall include hair cover, facemask, beard cover (if applicable), polypropylene or low shedding gown that closes in the back, shoe covers, and two layers of gloves with the outermost glove tested to meet ASTM D6978-05 standard. Where the documentation provided by CACI manufacturer does not require garbing, only the two glove requirement shall apply.

(h) If a compounding aseptic isolator is certified by the manufacturer to maintain ISO Class 5 air quality during dynamic operation conditions during compounding as well as during the transfer of ingredients into and out of the compounding aseptic isolator, then it may be placed into a non-ISO classified room. Individuals that use compounding aseptic isolators in this manner must ensure appropriate garbing, which consists of donning sterile gloves over the isolator gloves immediately before non-hazardous compounding. These sterile gloves must be changed by each individual whenever continuous compounding is ceased and before compounding starts again.

(i) Compounding aseptic isolator and compounding aseptic containment isolator used in the compounding of sterile drug preparations shall use unidirectional air flow patterns.

(ii) Viable surface sampling shall be done at least quarterly every six months for all sterile-to-sterile compounding and monthly quarterly for all non-sterile-to-sterile compounding. Volumetric Viable air sampling shall be done by impaction volumetric air sampling procedures which test a sufficient volume of air (400 to 1,000 liters) at each location and shall be done at least once every six months. Viable surface and volumetric viable air sampling shall be performed by a qualified individual who is familiar with the methods and procedures for surface testing and air sampling. Viable air sampling is to be performed under dynamic
conditions that simulate actual production. Surface sampling is to be performed under
dynamic conditions of actual compounding. When the environmental monitoring action levels
are exceeded, the pharmacy shall identify the CFUs at least to the genus level in addition to
conducting an investigation. Remediation shall include an immediate investigation of cleaning
and compounding operations and facility management.

The sterile compounding area is the pharmacy shall have a comfortable and well-
lighted working environment, which includes a room temperature of 20-22 degrees Celsius
(68-75 degrees Fahrenheit) or cooler to maintain comfortable conditions for compounding
personnel when attired in the required compounding garb.

Note: Authority Cited: Sections 4005 and 4127, Business and Professions Code. Reference:
Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code; and
Section 18944, Health and Safety Code.

To Amend § 1751.5 in Article 7 of Division 17 of Title 16 of the California Code of
Regulations to read as follows:

1751.5. Sterile Injectable Compounding Attire.

(a) When preparing cytotoxic agents, gowns and gloves shall be worn.

(b) (a) When compounding sterile drug products preparations from one or more non-sterile
ingredients the following standards must be met:

(1) Cleanroom garb Personal protective equipment consisting of a low non-shedding coverall
gown, head cover, face mask, facial hair covers (if applicable), and shoe covers must be worn
inside the designated area at all times, unless the compounding aseptic isolator or
compounding aseptic containment isolator manufacturer can provide written documentation,
based on validated environmental testing, that any component of the personal protective
equipment or personnel cleansing is not required.

(2) Cleanroom garb Personal protective equipment must be donned and removed outside the
designated area in an ante-area or immediately outside the segregated compounding area.
(3) Personnel shall don personal protective equipment in an order that proceeds from those activities considered the dirtiest to those considered the cleanest. The following order is to be followed unless the pharmacy has a procedure in place that documents a method equivalent to or superior to the method described here: The donning of shoe covers or dedicated shoes, head and facial hair covers and face masks shall be followed by the washing of hands and forearms up to the elbows for 30 seconds with soap and water, drying hands, and then the donning of a non-shedding gown.

(3)(4) Compounding personnel shall not wear any wrist, hand, finger, and or wrist other visible jewelry or piercing must be eliminated. If jewelry cannot be removed then it must be thoroughly cleaned and covered with a sterile glove.

(4) Head and facial hair must be kept out of the critical area or be covered.

(5) Gloves made of low-shedding materials are required. Sterile gloves that have been tested for compatibility with disinfection with isopropyl alcohol are required. Hand cleansing with a persistently active alcohol-based product followed by the donning of sterile gloves may occur within the ante or buffer area or cleanroom. Gloves are to be routinely disinfected with sterile 70 percent isopropyl alcohol before entering or re-entering the PEC and after contact with non-sterile objects. Gloves shall also be routinely inspected for holes, punctures, or tears and replaced immediately if such are detected.

(6) Individuals experiencing exposed rashes, sunburn, weeping sores, conjunctivitis, active respiratory infections, or those wearing cosmetics, nail polish, or artificial nails shall be excluded from the ISO Class 5 and ISO Class 7 compounding areas until their conditions are remedied.

(c) The requirements of subdivision (b) do not apply if a barrier isolator is used to compound sterile injectable products from one or more non-sterile ingredients.

(b) When preparing hazardous agents, appropriate gowns and personal protective equipment shall be worn regardless of the PECs used (e.g., biological safety cabinet and compounding aseptic containment isolator). Exceptions are as listed in 1751.4(g).

Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections
4005, 4036, 4037, 4051, 4052, and 4127, Business and Professions Code.

To Amend § 1751.6 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.6 Training of Sterile Injectable Compounding Staff, Patient, and Caregiver. Sterile Compounding Consultation; Training of Sterile Compounding Staff.

(a) Consultation shall be available to the patient and/or primary caregiver concerning proper use, storage, handling, and disposal of sterile injectable drug products preparations and related supplies furnished by the pharmacy.
(b) The pharmacist-in-charge shall be responsible to ensure that all pharmacy personnel engaging in compounding sterile injectable drug products preparations shall have training and demonstrated competence in the safe handling and compounding of sterile injectable drug products preparations, including cytotoxic hazardous agents if the pharmacy compounds products with cytotoxic hazardous agents.
(c) Records of training and demonstrated competence shall be available for each individual and shall be retained for three years beyond the period of employment.
(d) The pharmacist-in-charge shall be responsible to ensure the continuing competence of pharmacy personnel engaged in compounding sterile injectable drug products preparations.
(e) Pharmacies that compound sterile drug products from one or more non-sterile ingredients preparations must comply with the following training requirements:
(1) The pharmacy must establish and follow a written program of training and performance evaluation designed to ensure that each person working in the designated area has the knowledge and skills necessary to perform their assigned tasks properly. This program of training and performance evaluation must address at least the following:
(A) Aseptic technique.
(B) Pharmaceutical calculations and terminology.
(C) Sterile product preparation compounding documentation.
(D) Quality assurance procedures.
(E) Aseptic preparation procedures using media-fill tests which are as complicated as the most complex manipulations performed by staff and which contain the same amount or greater of volume transferred during the selected manipulations.

(F) Proper hand hygiene, gowning and gloving technique.

(G) General conduct in the controlled area.

(H) Cleaning, sanitizing, and maintaining of the equipment and used in the controlled area.

(I) Sterilization techniques for compounding sterile drug preparations from one or more non-sterile ingredients.

(J) Container, equipment, and closure system selection.

(2) Each person assigned to the controlled area engaged in sterile compounding must successfully complete practical skills training in aseptic technique and aseptic area practices. Evaluation must include written testing and a written protocol of periodic routine performance checks involving adherence to aseptic area policies and procedures. Each person’s proficiency and continuing training needs must be reassessed at least every 12 months. Results of these assessments must be documented and retained in the pharmacy for three years.

To Amend § 1751.7 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.7. Sterile Injectable Compounding Quality Assurance and Process Validation.

(a) Any pharmacy engaged in compounding sterile injectable drug products preparations shall maintain, as part of its written policies and procedures, a written quality assurance plan including, in addition to the elements required by section 1735.8, a documented, ongoing quality assurance program that monitors personnel performance, equipment, and facilities. The end product shall be examined on a periodic sampling basis as determined by the pharmacist-in-charge to assure that it meets required specifications. The Quality Assurance Program shall include at least the following:

(1) Procedures for cleaning and sanitization of the parenteral medication sterile preparation area.

(2) The storage of compounded sterile injectable products in the pharmacy and periodic documentation of refrigerator temperature.

(3) Actions to be taken in the event of a drug recall.

(4) Written justification of documentation justifying the chosen expiration beyond use dates for compounded sterile injectable drug products preparations.

(b) Each individual involved in the preparation of sterile injectable drug products preparations must first successfully demonstrate competency by successfully performing aseptic media-fill tests before being allowed to prepare sterile injectable drug products preparations. The validation process shall be carried out in the same manner as normal production, except that an appropriate microbiological growth medium is used in place of the actual product used during sterile preparation. The validation process shall be representative of all types of manipulations, products and batch sizes the individual is expected to prepare. The media fill testing process shall be as complicated as the most complex manipulations performed by staff and contain the same amount or greater of volume transferred during the compounding process. The same personnel, procedures, equipment, and materials must be involved. Media used must have demonstrated the ability to support...
and promote growth. Completed medium media samples must be incubated in a manner consistent with the manufacturer’s recommendations. If microbial growth is detected, then the employee’s sterile preparation process must be evaluated, corrective action taken and documented, and the validation process media-fill testing repeated. Personnel competency must be revalidated at least every twelve months for sterile to sterile compounding and at least every six months for individuals compounding sterile products from non-sterile ingredients. Aseptic work practice assessments via media fill tests must be revalidated, as appropriate to the circumstance or personnel found to be deficient, whenever the quality assurance program yields an unacceptable result, when the compounding process changes, equipment used in the compounding of sterile injectable drug products preparations is repaired or replaced, the facility is modified in a manner that affects airflow or traffic patterns, or whenever improper aseptic techniques are observed. Revalidation must be documented.

(c) All sterile compounding personnel must successfully complete an initial competency evaluation. In addition, immediately following the initial hand hygiene and garbing procedure, all compounding personnel must successfully complete a gloved fingertip sampling procedure (zero colony forming units for both hands) at least three times before initially being allowed to compound sterile drug preparations.

(d) Re-evaluation of garbing and gloving competency shall occur at least every 12 months for personnel compounding products made from sterile ingredients and at least every six months for personnel compounding products from non-sterile ingredients.

(e)(1) Batch-produced sterile injectable drug preparation compounded from one or more non-sterile ingredients except as provided in paragraph (2), non-sterile-to-sterile batch drug preparations shall be subject to documented end product testing for sterility and pyrogens and shall be quarantined until the end product testing confirms sterility and acceptable levels of pyrogens, per USP chapter 85 limits, before dispensing. This requirement of end product testing confirming sterility and acceptable levels of pyrogens prior to dispensing shall apply regardless of any sterility or pyrogen testing that may have been conducted on any ingredient or combination of ingredients that were previously non-sterile. Exempt from pyrogen testing are non-injectable ophthalmic and inhalation preparation.
(1) The following non-sterile-to-sterile batch drug preparations do not require end product testing for sterility and pyrogens:
(A) Preparations for self-administered ophthalmic drops in a quantity sufficient for administration to a single patient for 30 days or less.
(B) Preparations for self-administered inhalation in a quantity sufficient for administration to a single patient for 5 days or less.

Batch-produced sterile injectable drug products compounded from one or more non-sterile ingredients. Non-sterile-to-sterile batch drug preparations shall be subject to documented end product testing for sterility and pyrogens and shall be quarantined until the end product testing confirms sterility and acceptable levels of pyrogens, per USP chapter 85 limits, before dispensing. This requirement of end product testing confirming sterility and acceptable levels of pyrogens prior to dispensing shall apply regardless of any sterility or pyrogen testing that may have been conducted on any ingredient or combination of ingredients that were previously non-sterile.

(d) Batch-produced sterile to sterile transfers shall be subject to periodic testing through process validation for sterility as determined by the pharmacist-in-charge and described in the written policies and procedures.


To Amend § 1751.8 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.8. Beyond Use Dating for Sterile Compounded Drug Preparations.
In conformity with and in addition to the requirements and limitations of section 1735.2, subdivision (h), every sterile compounded drug preparation shall be given and labeled with a beyond use date that does not exceed the expiration date or beyond use date provided by the manufacturer for any component in the preparation, and that, in the absence of passing a sterility test in accordance with standards for sterility testing found in Chapter 797 of the United
States Pharmacopeia – National Formulary (USP37-NF32) Through 2nd Supplement (37th
Revision, Effective December 1, 2014), hereby incorporated by reference, that would justify a
more an extended beyond use date, conforms to the following limitations:
(a) The beyond use date shall specify that storage and exposure periods cannot exceed 48
hours at controlled room temperature, 14 days at controlled cold temperature, and 45 days
at controlled freezer temperature in solid frozen state, where the sterile compounded drug
preparation is compounded solely with aseptic manipulations and all of the following apply:
(1) The preparation is compounded entirely within an ISO Class 5 PEC located in an ISO Class 7
buffer area or cleanroom with an ante-area or compounded entirely within a CAI or CACI
which meets the requirements in 1751.4(f)(1)-(3), using only sterile ingredients, products,
components, and devices; and
(2) The compounding process involves transferring, measuring, and mixing manipulations
using not more than three commercially manufactured packages of sterile preparations and
not more than two entries into any one sterile container or package of sterile preparations or
administration containers/devices to prepare the drug preparation; and
(3) Compounding manipulations are limited to aseptically opening ampules, penetrating
disinfectected stoppers on vials with sterile needles and syringes, and transferring sterile liquids
in sterile syringes to sterile administration devices, package containers of other sterile
preparations, and containers for storage dispensing.
(b) The beyond use date shall specify that storage and exposure periods cannot exceed 30
hours at controlled room temperature, 9 days at controlled cold temperature, and 45 days at
controlled freezer temperature in solid frozen state, where the sterile compounded drug
preparation is compounded solely with aseptic manipulations and all of the following apply:
(1) The preparation is compounded entirely within an ISO Class 5 PEC located in an ISO Class 7
buffer area or cleanroom with an ante-area or compounded entirely within a CAI or CACI
which meets the requirements in 1751.4(f)(1)-(3), using multiple individual or small doses of
sterile preparations combined or pooled to prepare a compounded sterile preparation that
will be administered either to multiple patients or to one patient on multiple occasions; and
(2) The compounding process involves complex aseptic manipulations other than the
(3) The compounding process requires unusually long duration such as that required to complete dissolution or homogenous mixing.

(c) The beyond use date shall specify that storage and exposure periods cannot exceed 24 hours at controlled room temperature, 3 days at controlled cold temperature, and 45 days at controlled freezer temperature in solid frozen state, where the sterile compounded drug preparation is compounded solely with aseptic manipulations using non-sterile ingredients, regardless of intervening sterilization of that ingredient and the following applies: including manufactured preparations not intended for sterile routes of administration, or non-sterile devices, before terminal sterilization, or where the sterile compounded drug preparation lacks effective antimicrobial preservatives.

For the purposes of this subdivision, “non-sterile” includes sterile contents of commercially manufactured preparations, sterile surfaces of devices, and containers for the preparation, transfer, sterilization, and packaging of compounded sterile preparations, that are exposed to worse than ISO Class 5 air quality for more than one hour.

(1) The preparation is compounded entirely within an ISO Class 5 PEC located in an ISO Class 7 cleanroom with an ante-area or compounded entirely within a CAI or CACI which meets the requirements in 1751.4(f)(1)-(3).

(d) The beyond use date shall specify that storage and exposure periods cannot exceed 12 hours where the sterile compounded drug preparation is compounded solely with aseptic manipulations and all of the following apply:

(1) The preparation was compounded entirely within an ISO Class 5 PEC that is located in a segregated sterile compounding area and restricted to sterile compounding activities, using only sterile ingredients, components, and devices, by personnel properly cleansed and garbed; and

(2) The compounding process involves simple transfer of not more than three commercially manufactured packages of sterile nonhazardous preparations or diagnostic radiopharmaceutical preparations from the manufacturer’s original containers; and

(3) The compounding process involves not more than two entries into any one container.
or package (e.g., bag, vial) of sterile infusion solution or administration container/device.

(e) Where any sterile compounded drug preparation was compounded either outside of an ISO class 5 PEC or under conditions that do not meet all of the requirements for any of subdivisions (a) through (e), the sterile compounded drug preparation shall be labeled “for immediate use only” and administration shall begin no later than one hour following the start of the compounding process. Unless the “immediate use” preparation is immediately and completely administered by the person who prepared it or immediate and complete administration is witnessed by the preparer, the preparation shall bear a label listing patient identification information, the names and amounts of all ingredients, the name or initials of the person who prepared the compounded sterile preparation, and the exact one-hour beyond use date and time. If administration has not begun within one hour following the start of the compounding process, the compounded sterile preparation shall be promptly, properly, entirely, and safely discarded. This provision does not preclude the use of a PEC to compound an “immediate use” preparation. A PEC used solely to compound ‘immediate use’ preparations need not be placed within an ISO Class 7 buffer area or cleanroom, with an ante-area.

(1) Such “immediate use” preparations shall be compounded only in those limited situations where there is a need for immediate administration of a sterile preparation compounded outside of an ISO class 5 environment and where failure to administer could result in loss of life or intense suffering. Any such compounding shall be only in such quantity as is necessary to meet the immediate need and the circumstance causing the immediate need shall be documented in accordance with policies and procedures.

To Add § 1751.9 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.9 Single-Dose and Multi-Dose Containers; Limitations on Use

(a) Single-dose ampules are for immediate use only, and once opened shall not be stored for any time period.

(b) Unless otherwise specified by the manufacturer, any single-dose container of a compounded sterile drug preparation other than an ampule, such as a bag, bottle, syringe or vial, shall be used in its entirety or its remaining contents shall be labeled with a BUD and discarded within the following time limit, depending on the environment:

(1) When needle-punctured in an environment with air quality worse than ISO Class 5, within one (1) hour;

(2) When needle-punctured in an environment with ISO Class 5 or better air quality, within six (6) hours.

(c) Unless otherwise specified by the manufacturer, a multi-dose container stored according to the manufacturer’s specifications shall be used in its entirety or its remaining contents shall be labeled with a BUD and discarded within twenty eight (28) days from initial opening or puncture. Any multi-dose container not stored according to the manufacturer’s specifications shall be discarded immediately upon identification of such storage circumstance.

To Amend § 1751.10 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:


In any pharmacy engaged in compounding sterile injectable drug products preparations, there shall be current and appropriate reference materials regarding the compounding of sterile injectable drug products preparations located in or immediately available to the pharmacy.


To Add Article 7.5 of Division 17 of Title 16 of the California Code of Regulations to read as follow

Article 7.5 Furnishing for Home Administration

To Amend § 1751.10 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.10. 1752. Furnishing to Parenteral Patient at Home.

Subject to all provisions of this article, a pharmacist may carry and furnish to a patient at home dangerous drugs, other than controlled substances, and devices for parenteral therapy when the dangerous drug or device is one currently prescribed for the patient.

To Amend § 1751.11 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.11. 1753. Furnishing to Home Health Agencies and Licensed Hospices.

Subject to the following conditions, a licensed pharmacy may furnish to a home health agency licensed under provisions of Chapter 8 (commencing with section 1725 of Division 2 of the Health and Safety Code) or to a hospice licensed under provisions of Chapter 8.5 (commencing with section 1745 of Division 2 of the Health and Safety Code) dangerous drugs for parenteral therapy other than controlled substances, in a portable container for furnishing to patients at home for emergency treatment or adjustment of parenteral drug therapy by the home health agency or licensed hospice.

(a) The pharmacy, having ownership and responsibility for the portable containers, shall ensure that each portable container is:

(1) furnished by a registered pharmacist;

(2) sealed in such a manner that a tamper-proof seal must be broken to gain access to the drugs;

(3) under the effective control of a registered nurse, pharmacist or delivery person at all times when not in the pharmacy;

(4) labeled on the outside of the container with a list of the contents;

(5) maintained at an appropriate temperature according to United States Pharmacopeia Standards (1995, 23rd Revision), and protected at all times from extreme temperatures that could damage the contents.

(b) The portable container may contain up to:

(1) 1000mL of 0.9% sodium chloride intravenous infusion in containers of a size determined by the pharmacy;

(2) 1000mL of 5% dextrose in water injection in containers of a size determined by the pharmacy;

(3) two vials of urokinase 5000 units;

(4) Each of the following items shall be in sealed, unused containers; the furnishing pharmacy
may select any or all of these dangerous drugs in up to five dosage units for inclusion in the
sealed, portable container:

(A) heparin sodium lock flush 100 units/mL;
(B) heparin sodium lock flush 10 units/mL;
(C) epinephrine HCl solution 1:1000;
(D) epinephrine HCl solution 1:10,000;
(E) diphenhydramine HCl 50mg/mL;
(F) methylprednisolone 125mg/2mL;
(G) normal saline, preserved, up to 30 mL vials;
(H) naloxone 1mg/mL 2 mL;
(I) droperidol 5mg/2mL;
(J) prochlorperazine 10mg/2mL;
(K) promethazine 25mg/mL;
(L) dextrose 25gms/50mL;
(M) glucagon 1mg/mL;
(N) insulin (human) 100 units/mL;
(O) bumetamide 0.5mg/2mL;
(P) furosemide 10mg/mL;
(Q) EMLA Cream 5 gm tube;
(R) Lidocaine 1 percent 30mL vials.

(5) The pharmacy shall ensure that the specific dangerous drugs and quantities to be included
in the portable container are listed in the home health agency's or licensed hospice's policies
and procedures.

(c) The pharmacy shall not supply a portable container to a home health agency or licensed
hospice which does not:

(1) implement and maintain policies and procedures for:

(A) the storage, temperature stability and transportation of the portable container;

(B) the furnishing of dangerous drugs from the portable container upon the written or oral
authorization of a prescriber; and
(C) a specific treatment protocol for the administration of each medication contained in the portable container.

(2) have the policies, procedures and protocols reviewed and revised (as needed) annually by a group of professional personnel including a physician and surgeon, a pharmacist and a registered nurse.

(d) A copy of these policies, procedures and protocols shall be maintained by the furnishing pharmacy from each home health agency or licensed hospice for which the pharmacy furnishes portable containers.

(e) In cases where a drug has been administered to a patient pursuant to the oral order of a licensed prescriber, the pharmacy shall ensure that the oral order is immediately written down by the registered nurse or pharmacist and communicated by copy or fax within 24 hours to the furnishing pharmacy, with a copy of the prescriber-signed document forwarded to the dispensing pharmacy within 20 days.

(f) The pharmacy shall ensure that within seven days (168 hours) after the seal has been broken on the portable container, the home health agency's director of nursing service or a registered nurse employed by the home health agency or licensed hospice returns the container to the furnishing pharmacy. The furnishing pharmacy shall then perform an inventory of the drugs used from the container, and if the container will be reused, must restock and reseal the container before it is again furnished to the home health agency or licensed hospice.

(g) The furnishing pharmacy shall have written policies and procedures for the contents, packaging, inventory monitoring, labeling and storage instructions of the portable container.

(h) The furnishing pharmacy shall ensure that the home health agency or licensed hospice returns the portable containers to the furnishing pharmacy at least every 60 days for verification of product quality, quantity, integrity and expiration dates, or within seven days (168 hours) after the seal has been broken.

(i) The furnishing pharmacy shall maintain a current inventory and record of all items placed into and furnished from the portable container.
To Amend §1751.12 in Article 7 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1751.12 1754. Obligations of a Pharmacy Furnishing Portable Containers.

(a) A licensed pharmacy shall not issue portable containers to any home health agency or licensed hospice unless the home health agency or licensed hospice complies with provisions of section 1751.11.

(b) A licensed pharmacy shall cease to furnish portable containers to a home health agency or licensed hospice if the home health agency or licensed hospice does not comply with provisions of section 1751.11.

45-Day
Comments
(b) "Compounding" does not include reconstitution of a drug pursuant to a manufacturer’s direction(s) for oral, rectal, topical, or injectable administration, nor does it include the sole act of tablet splitting or crushing, capsule opening, or the addition of flavoring agent(s) to enhance palatability.

In a general sense, this definition is consistent with the definition of "compounding" found in 21 USC 353a, which is the section of the federal law that deals with compounding in pharmacies. However, the language dealing with activities that are excluded from compounding is slightly different. 21 USC 353a(e) reads: "As used in this section, the term "compounding" does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product's manufacturer and other manufacturer directions consistent with that labeling."

This federal definition is somewhat broader than the language at the beginning of the proposed §1735(b), which appears to be limited to "reconstitution," which is not further defined in the proposed regulation. Without further clarification, this could cause confusion regarding the preparation of certain commercially available products, such as Benzamycin® or Phospholine Iodide® (two products from my earlier days as a practicing pharmacist) which involve preparation prior to dispensing that may not meet all definitions of "reconstitution." To illustrate the possible confusion that can occur, I've included excerpts from the labeling for Benzamycin® and Phospholine Iodide® which show the manufacturer’s directions for preparation for these products, as well as two common, but inconsistent, definitions of "reconstitution.

Continued on next Row.

Continued from previous Row.

The first question then, is whether preparation of commercially available products consistent with manufacturer directions is, or should, be excluded from the definition of "compounding" even if those directions call for more than simple "reconstitution." A further question is whether the exemption should be limited to "oral, rectal, topical or injectable administration" as included in the proposed §1735(b) or whether it should extend to products intended for use in the eye or ear, which is consistent with the federal law.

Should the Board feel that preparation of any product that is consistent with manufacturer labeling should be excluded from the definition of compounding, we suggest the following amendment of §1735(b) to make it consistent with the federal language found at 21 USC 353a(e):

"(b) "Compounding" does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling does not include reconstitution of a drug pursuant to a manufacturer's direction(s) for oral, rectal, topical, or injectable administration, nor does it include the sole act of tablet splitting or crushing, capsule opening, or the addition of flavoring agent(s) to enhance palatability."

Should the Board decide to leave the language as proposed, some clarification of the intent of the language and the intended definition of "reconstitution" should be provided as a reference for pharmacists and the board's inspectors.

If the Board believes these products should be included within the definition of "compounding," the Board should provide a clear indication of whether the manufacturer’s directions and labeling are adequate to comply with the compounding documentation included elsewhere in these proposed regulations.
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1735(b)      | Doug O'Brien  
Kaiser Permanente | The proposed language is missing some very common and important categories of products that the standards of practice do not call for extra specified conditions, such as Phospholine iodide eye drops. Relying on the term “topical” to include such categories is unrealistic and adding some specific terms will reduce confusion.  
Recommendation: Add wording to indicate that the examples are not all inclusive and specifically the categories of “ophthalmic” and “otic” to the list of products where “Compounding” does not include “reconstitution”. Use the following language: “Compounding” does not include reconstitution of a drug pursuant to a manufacturer’s direction(s), such as for ophthalmic otic, oral, rectal, topical, or injectable administration, nor does it include the sole act of tablet splitting or crushing, capsule opening, or the addition of flavoring agent(s) to enhance palatability.  
Rationale: Several of the most popular products are ophthalmic products that only have to be reconstituted following manufacturer’s instructions. |
| 1735.1       | Julie Brosz | Adding the new definitions would make references in other regulations more specific and clear.  
The proposed additional definitions (indicated by dashes here) would be plugged into the appropriate subsection of 1735.1, and the lettering would be rearranged accordingly.  
(-) “Controlled area” or “designated area” for sterile processing means any area where the environment is specifically controlled to prevent contamination of sterile compounds. Areas such as the cleanroom, CAI, or CACI would be included in this definition, as would an ante room requiring special preparation to enter.  
(-) “Sterile compounding personnel” refers to personnel who are actively preparing sterile compounds in the controlled area, or directly supervising such a person in the controlled area. |
| 1735.1       | BJ Bartleson  
California Hospital Association | On January 27, 2015, a sterile compounding inspection took place at El Camino Hospital in Mountain View, CA. Certain statements in the inspection report implied that all pharmacists in the department, regardless of whether or not they actually worked in the sterile processing environment, had to pass the rigorous practical test involving long standing times and repeated manipulation of needles.  
The interpretation that this is a universal requirement makes it difficult or impossible for those with disabilities to work in any capacity in a hospital pharmacy. We do not believe the intent of the regulation is to preclude employers from providing reasonable accommodations to disabled personnel.  
To correct this situation, for Dr. Brosz and other disabled pharmacists similarly situated, we are recommending some changes in Title 16 that would make clear that the hands-on aseptic testing requirements are limited to those actually working or supervising inside the controlled sterile processing environment, rather than a universal requirement that would exclude disabled people from working in a hospital pharmacy at all. |
| 1735.1       | BJ Bartleson  
California Hospital Association | Insert new section after (p), titled “Fully automated IV Robotics”- means a system where the actual compounding is done in an enclosed ISO 5 area by a machine with programming that allows the product to be compounded without human touch in the compounding space”  
IV robotics requires a definition in order to have instructions for issues such as cleaning. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1735.1</strong></td>
<td>Lynn Paulsen</td>
<td>CACI/CAI refers to ventilation building requirements. Requesting a delay until USP 800 to finalized. It is unclear why the ventilation requirements apply to the CACI/CAI and not the biological safety cabinets. Additionally, a definition needs to be added for &quot;Automation or Robotics.&quot; Language provided by CHA</td>
</tr>
<tr>
<td><strong>1735.1(a)</strong></td>
<td>Julie Brosz</td>
<td>(a) &quot;Ante-area&quot; means an ISO Class 8 or better air quality where personnel sterile compounding personnel hand hygiene and garbing procedures, staging of components, and other high-particulate-generating activities are performed ... To more clearly differentiate the duties and requirements for those involved in sterile compounding, we have added definitions of “sterile compounding personnel” and “controlled area,” and refer to these terms throughout the regulations that apply exclusively to sterile compounding.</td>
</tr>
<tr>
<td><strong>1735.1(c)</strong></td>
<td>Julie Brosz</td>
<td>(c) “Biological Safety Cabinet (BSC)” means a ventilated cabinet for compounded sterile drug preparations, having an open front with inward airflow for personnel sterile compounding personnel protection, downward HEPA-filtered laminar airflow for product protection, and HEPA-filtered exhausted air for environmental protection.</td>
</tr>
</tbody>
</table>
| **1735.1(d)**| Doug O’Brien  
Kaiser Permanente | Recommendation: Adopt the USP Chapter 797 definition for buffer area, “An area where the primary engineering control is located. Activities that occur in this area include the preparation and staging of components and supplies used when compounding CSPs.”  
Rationale: The proposed definition is not in alignment with USP Chapter 797, which allows for the compounding of hazardous drugs in a buffer area that utilizes the airflow displacement method.  
The result of this definition (taken in context with the definitions of cleanroom and segregated compounding area) is that neither a CACI nor a BSC can be used to prepare chemotherapy in a cleanroom configuration that utilizes the airflow displacement method.  
This definition imposes significant and very expensive new requirements as cleanrooms utilizing the airflow displacement method will need to be remodeled to separate the buffer area from the ante-area with walls/doors.  
This change in definition would necessitate remodeling and construction costs exceeding $60 million for our organization. |
| **1735.1(d)**| Douglas Barcon  
Barcon & Associates | Change “The principle of displacement airflow shall be employed” to “Instead of physical separation from the ante-area, the principle of displacement airflow shall be employed.” Without such a change, the regulation states that a buffer area could only use displacement airflow, which is incorrect.  
Alternate change to above: After “The principle of displacement airflow shall be employed” add to the sentence “where there is no physical separation from the ante-areas by walls or doors.”  
To improve the definition of a “buffer area”, change the first sentence to: “Buffer area” means an area where the primary engineering control (PEC) is located which provides at least an ISO Class 7 or better air quality and maintains segregation from the adjacent ante-area by means of specific pressure differentials.”  
Inclusion of the ISO Class 7 or better air quality is a necessary requirement of a buffer area for sterile compounding in USP 797 and is the location of the PEC, even though it is duplicated in the definition of a cleanroom. Also, remove “physically” because “located” alone confers the same meaning. |
Concerned about the language “for hazardous compounds, or for chemotherapy compounds”. To not permit the displacement concept to maintain clean room area requirements will have significant impact for some facilities in terms of remodeling and construction costs. Outside of the costs and time necessary to complete facility modifications to meet this requirement, there could be negative impacts if a pharmacy could not continue to provide the potentially life-saving “hazardous” medications needed as a facility works towards gaining compliance with the requirement. Some geographic areas of the State may not have a nearby health facility to provide this type of service or the ability to handle the order volume currently managed by the Pharmacy.

Understanding a key element of proposed USP <800> is to require that hazardous drugs be stored in a negative or normal/pressure, and compounding must be completed in certified biological safety cabinets or compounding aseptic containment isolators in a separate room with negative pressure, attempts to harmonize State with Federal Standards may be indicated. However, if the BOP adopts the modified text as proposed and there are not reasonable timelines and expectations for compliance established, it could severely limit patient access to needed care or place tremendous burdens on patients and those supporting their care to travel to a facility that is compliant with the regulation.

Please consider the following clarifying information:
the verbiage in USP 797 specific to “displacement concept” reads, “The displacement concept shall not be used for high-risk compounding.” The reference cited “ISO 14644-4:2001 Cleanrooms and associated controlled environments-Design, construction, and start-up” includes section A.5.2 which describes the displacement concept. The displacement concept is described in this reference as a means to effectively separate clean and less clean adjacent zones without any mention of hazardous compounds or chemotherapy. As such, the term “high-risk” should be taken to mean high risk of microbial contamination as described in USP <797>.

Our facility currently meets the “low volume” exemption described in USP <797>, hazardous CSP prepared in an ISO 5 CACI using closed-system transfer devices. The PEC (CACI) is located in the ISO 7 buffer area (located in a non-negative pressure clean room). The buffer area is not physically separated from the ante-area, the principle of displacement airflow is employed.

Please delete the language “for hazardous compounds, or for chemotherapy compounds” and consider reintroducing at a later time after fully assessing impacts to Pharmacies holding Sterile Compounding Licenses in this state and establishing reasonable timelines for gaining compliance.

“Buffer area” means an area which maintains segregation from the adjacent ante-area by means of specific pressure differentials (A minimum differential positive pressure of 0.02- to 0.05- inch water column is required). If physical separation (walls/doors) does not exist between the buffer and ante area, the principle of displacement airflow shall be employed. This concept utilizes a low pressure differential, high airflow principle. Using displacement airflow typically requires an air velocity of 40ft per minute or more from the buffer area across the line of demarcation into the ante-area. The displacement concept may not be used to maintain buffer area requirements for sterile compounds which originate from any ingredient that was at any time non-sterile, regardless of intervening sterilization of the ingredient, for hazardous compounds, or for chemotherapy compounds.

In the absence of a physically separated buffer and ante area for medication preparation, USP 797 allows the use of displacement airflow. Application of this to hazardous drug areas is essential for organizations that don't have a separate room to allow for hazardous medication preparation for cancer patients. In the board response to comments, the terms high-risk and hazardous are used interchangeably (Attachment 2- third response to comment on 1735.1(f)).

(FYI: Attachment 2 was not provided.)
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1735.1(d)</td>
<td><strong>University Compounding Pharmacy</strong>&lt;br&gt;Joe Grasela</td>
<td>Definition for &quot;Buffer area&quot; and &quot;Clean room&quot; in USP 797 are used interchangeably (pg 12 of USP 797). It would be best to clarify that a &quot;Buffer area&quot; is a designated area with no separated doors or walls with a line of demarcation from the Ante room while a &quot;Clean room&quot; is a physical room with walls and/or door separation from the Ante room that allows for compounding of Hazardous and High risk preparations. We associate our &quot;clean room/buffer room&quot; with walls and the door as our line of demarcation that allows us to compound &quot;Hazardous&quot; or &quot;High risk&quot; compounds. With this clarification, we would then term our sterile compounding room as a &quot;clean room&quot; as opposed to a &quot;buffer area&quot;. When USP 800 is released, your current definition of “clean room” doesn’t address the negative pressure room requirements (ie: 0.01-0.03 inches of water column, externally vented, 30 ACPH). (d) &quot;Buffer area&quot; means an area which maintains segregation from the adjacent ante area by means of specific pressure differentials. The principle displacement airflow shall be employed. This concept utilizes a low pressure differential, high airflow principle...The displacement concept may not be used to maintain buffer area requirements for sterile compounds which originate from any ingredient that was at any time non-sterile, regardless of intervening sterilization of the ingredient, for hazardous compounds, or for chemotherapy compounds.</td>
</tr>
<tr>
<td>1735.1(e)</td>
<td><strong>Brian Warren</strong>&lt;br&gt;California Pharmacist Association</td>
<td>(e) “Bulk drug substance” means any substance that, when used in the preparation of a compounded drug preparation, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug, but the term does not include any intermediate used in the synthesis of such substances. An inactive ingredient does not become active.</td>
</tr>
<tr>
<td>1735.1(f)</td>
<td><strong>Doug O'Brien</strong>&lt;br&gt;Kaiser Permanente</td>
<td>This definition is misleading and inaccurate, because it states that a cleanroom must provide ISO Class 7 or better air quality. There are other acceptable configurations of cleanrooms. For example, a cleanroom could also be a physically separate room that contains a buffer area, in which the air quality is ISO Class 7 or better; and an ante area, in which the air quality is ISO Class 8 or better. Displacement airflow concept described in 1735.1 (d) could be used. Recommendation: Adopt the USP Chapter 797 definition for cleanroom: &quot;A room in which the concentration of airborne particles is controlled to meet a specified airborne particulate cleanliness class. Microorganisms in the environment are monitored so that a microbial level for air, surface, and personnel gear are not exceeded for a specified cleanliness class.” This definition accommodates all acceptable cleanroom configurations Remodeling and construction costs exceeding $10 million to convert existing cleanrooms to provide ISO Class 7 air quality.</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1735.1(f)</td>
<td><strong>University Compounding Pharmacy</strong>&lt;br&gt;Joe Grasela</td>
<td>Definition for &quot;Buffer area&quot; and &quot;Clean room&quot; in USP 797 are used interchangeably (pg 12 of USP 797). It would be best to clarify that a &quot;Buffer area&quot; is a designated area with no separated doors or walls with a line of demarcation from the Ante room while a &quot;Clean room&quot; is a physical room with walls and/or door separation from the Ante room that allows for compounding of Hazardous and High risk preparations. We associate our &quot;clean room/buffer room&quot; with walls and the door as our line of demarcation that allows us to compound &quot;Hazardous&quot; or &quot;High risk&quot; compounds. With this clarification, we would then term our sterile compounding room as a &quot;clean room&quot; as opposed to a &quot;buffer area&quot;. When USP 800 is released, your current definition of &quot;clean room&quot; doesn't address the negative pressure room requirements (ie: 0.01-0.03 inches of water column, externally vented, 30 ACPH). (f) &quot;Clean room&quot; means a physically separate room with walls and doors that provides at least an ISO Class 7 or better air quality where the primary engineering control (PEC) is physically located. Minimum differential positive pressure of 0.02-0.05 inch water column is required.</td>
</tr>
<tr>
<td>1735.1(f)</td>
<td><strong>Douglas Barcon</strong>&lt;br&gt;Barcon &amp; Associates</td>
<td>Change to “A minimum differential positive pressure of 0.02-to 0.05-inch water column is required” to “A minimum differential positive pressure of 0.02-to 0.05-inch water column is required to segregate the room from the surrounding unclassified spaces to reduce the risk of contaminants being blown, dragged, or otherwise introduced into the filtered unidirectional airflow environment.”</td>
</tr>
<tr>
<td>1735.1(g)</td>
<td><strong>Douglas Barcon</strong>&lt;br&gt;Barcon &amp; Associates</td>
<td>Change to “Compounding Aseptic Isolator (CAI)” means a form of isolator specifically designed for compounding non-hazardous pharmaceutical ingredients or preparations.” A negative pressure CACI should be used to compound hazardous pharmaceutical ingredients or preparations. A CAI should not be used to compound antineoplastic hazardous drugs per draft USP 800 revision Fall 2014 (C151881).</td>
</tr>
<tr>
<td>1735.1(h)</td>
<td><strong>Douglas Barcon</strong>&lt;br&gt;Barcon &amp; Associates</td>
<td>After volatile, add &quot;, particle-generating, aerosol-producing, or sterile” This is a composite of board of pharmacy text and USP 800 revision Fall 2014 (C151881) sections 5.3.1 and 5.3.2.</td>
</tr>
<tr>
<td>1735.1(j)</td>
<td><strong>Bruce Lepley</strong>&lt;br&gt;Community Regional Pharmacy</td>
<td>Reason for Concern: In the May 2015 Compilation version, what was omitted was “or a range otherwise specified by the pharmaceutical manufacturer.” We believe that this is verbiage that should be kept to encapsulate all of the scenarios where it is warranted to store certain medications outside of the “-25 C to -10 C” range. Solution: Reinsert the verbiage “or a range otherwise specified by the pharmaceutical manufacturer” to better encapsulate all possible scenarios.</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| 1735.1(j)    | Douglas Barcon Barcon & Associates | Cannot have two definitions for "controlled freezer temperature." Use of "or" creates two definitions. Note that there is no definition of "controlled freezer temperature" in USP General Chapter 659 Packaging and Storage Requirements, USP 797, or the general notices in USP-37 NF-32.  
Should delete the word "controlled" from definition and leave remainder of text intact to be consistent with USP 797. Delete "manufacturer" and replace with "manufacturer(s) of the respective products."  
There is some concern that products which specify a temperature range colder than -25 degrees C on the lower end of the range, such as a vaccine at -40 degrees C, could be comiled at the colder temperature in the same freezer with products that specify -20 degrees C at the low end of the range, and this could jeopardize stability of the product or container with the storage limitation of -20 degrees C if stored colder than -20 degrees C. A separate freezer may be necessary to accommodate products with -40 degree C storage conditions to avoid comingling. |
| 1735.1(l)    | Douglas Barcon Barcon & Associates | This definition precludes a pharmacy from compounding a sterile preparation, such as premixed large volume intravenous solutions and for example, a 1 gram cefazolin or ceftriaxone antibiotic IVPB, if a manufacturer provides these as frozen IVPB products or inactivated IVPB form. Proprietary bag-vial systems such as ADD-Vantage, Mini-Bag Plus, and others require physical attachment to the infusion bag and should not be considered a commercially available compounded product in the regulation, or many compounded antibiotic IVPBs would be considered a copy. Also need to comply with the Drug Quality and Security Act regarding sterile preparations demonstrably difficult to compound.  
Suggest changing to: “Copy or essentially a copy” of a commercially available drug product includes all preparations that are comparable in active ingredients and dosage form to commercially available drug products, except premixed large volume intravenous solutions that are not demonstrably difficult to compound; premixed, inactivated, or frozen small volume parenteral products; or proprietary bag-vial systems such as ADD-Vantage, AddEASE, Mini-Bag Plus, and others; and does not include any preparations in which there has been a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by a prescribing practitioner, between that compounded preparation and the comparable commercially available drug product. |
| 1735.1(m)    | Lynn Paulsen | Should occur "every" day and not just when the pharmacy is open. |
| 1735.1(m)    | BJ Bartleson California Hospital Association | “Daily “means occurring every day.  
Pharmacies must be responsible to check refrigerated temperatures every day- the term operating may be interpreted as either open that day or operating as a licensed pharmacy and therefore should be removed. |
| 1735.1(n)    | Brian Warren California Pharmacist Association | (n) “Dosage unit” means a quantity sufficient for one administration to one patient, except that for self-administered ophthalmic drops, a quantity sufficient for 30 days or less shall be considered one dosage unit.  
Suggested modification to conform with modifications suggested to Section 1751.7(e) (see below). Further, substantive provisions (i.e., requirements and exceptions) should be placed in the substantive provisions of the regulations, not the definitions (see Martineau R. and Salerno M., Legal, Legislative, and Rule Drafting in Plain English, Thomson West, 2005). By placing the exception for self-administered ophthalmic drops in the definitions section, pharmacists may not understand its impact. |
<p>| 1735.1(q)    | Julie Brosz | (q) “Gloved fingertip sampling” means a process whereby compounding Sterile Compounding Personnel lightly press each fingertip and thumb onto appropriate growth media … |</p>
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1735.1(r)</td>
<td>Douglas Barcon</td>
<td>In order to bring in line with the NIOSH List of Anti-Neoplastic and Other Hazardous Drugs document and reinforce and clarify the regulation, suggest changing definition to include hazardous drugs portion too: “Hazardous” means all anti-neoplastic agents and other hazardous drugs as identified by the National Institute for Occupational Safety and Health (NIOSH) as meeting the criteria for a hazardous drug and any other drugs, compounds, or materials identified as hazardous by the pharmacist-in-charge. This change also provides guidance to the PIC in regard to hazardous drugs that are not anti-neoplastic agents.</td>
</tr>
<tr>
<td>1735.1(s)</td>
<td>Lynn Paulsen</td>
<td>It is unclear why both integrity and potency (y) are defined separately.</td>
</tr>
</tbody>
</table>
| 1735.1(t)    | Doug O'Brien | The wording of this definition is confusing and requires clarification. We believe “lot” could be interpreted two different ways. 
1. It could be interpreted to include different types of preparations that are prepared during one uninterrupted continuous cycle of compounding. A typical example of this interpretation in a hospital pharmacy: compounding four doses of azithromycin 500 mg/250mL dextrose 5% for four different patients, and two doses of famotidine 40 mg in 250mL dextrose 5% 250mL for one patient, and five doses of furosemide 100mg/100mL dextrose 5% for five different patients. All of these would be prepared in an uninterrupted continuous cycle of compounding.
Recommendation: If the above example is the intended interpretation, then we recommend this language: “Lot” means one or more different compounded drug preparation(s) prepared during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s).”
2. It could be interpreted to mean a single type of drug preparation compounded during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s). Using the example above, four doses of azithromycin 500 mg/250mL dextrose 5% for four different patients would be considered one lot.
Recommendation: If interpretation #2 is correct, then we recommend this language: “Lot” means a single type of drug preparation(s) prepared during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s).” |
| 1735.1(t)    | BJ Bartleson | “Lot” designation should be limited to the products made in anticipation of an order and cannot be tracked any other way. For example, a lot should be differentiated from six 1.5 gram Vancomycin doses made for six specific patients in a hospital pharmacy or six doses made for a patient at home. |
| 1735.1(t)    | William Stuart | Recommend: “Lot” means two or more compounded drug preparation(s) prepared during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s).
Rationale: Lot being “one or more” would encompass every patient-specific prescription or unit of one. This would require each prescription to undergo testing. This clause seems to be directed towards covering all batches but is unknowingly infringing onto patient-specific prescriptions. Testing patient-specific prescriptions would increase the volume needed to prepare, which would increase the amount of drug needed. The testing and the increase in the amount of drug would needlessly raise the price and delay of the therapy. The above recommendation will also align with the use of “two or more” in the definition of “Non-sterile-to-sterile batch” in 1735.1(v). |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1735.1(t)</td>
<td>Katherine Palmer</td>
<td>&quot;Lot&quot; means one or more &quot;non-sterile to sterile batch&quot; which means any compounded drug preparation containing two or more dosage units with any ingredient that was at any time non-sterile, regardless of intervening sterilization of that ingredient. compounded drug preparation(s) during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s). OR Alternatively, recommend changing definition of &quot;lot&quot; to &quot;greater than one dose&quot; in order to ensure timely preparation of compounded drugs to treat emergency patient's conditions where immediate administration of medications is essential. When medications are prepared as single doses, time is of the essence and documentation requirements for a lot would delay patient treatment. &quot;Lot&quot; means one or more &quot;greater than one dose&quot; of compounded drug preparation prepared in anticipation of immediate patients needs compounded drug preparation(s) during one uninterrupted continuous cycle of compounding from one or more common active ingredient(s).</td>
</tr>
<tr>
<td>1735.1(u)</td>
<td>Julie Brosz</td>
<td>(u) &quot;Media-fill test&quot; means a test that mimics compounding procedures using a growth-based media to demonstrate that aseptic techniques of compounding personnel Sterile Compounding Personnel or processes routinely employed do not result in microbial contamination. Recommend: &quot;Media-fill test&quot; means a test that mimics compounding procedures using a growth-based media to demonstrate that aseptic techniques of compounding personnel or processes routinely employed do not result in microbial contamination. To be valid, media-fill tests must be conducted on both the most routine and the most challenging compounding procedures performed. The most routine procedure is not referenced beyond this definition nor in USP &lt;797&gt;. We recommend removing the most routine procedure to remain consistent with the following uses of media-fill tests in the proposed text and USP: 1751.6(e)(1)(E) &quot;Aseptic preparation procedures using media-fill tests which are as complicated as the most complex manipulations performed by staff and which contain the same amount or greater volume transferred during the selected manipulations.&quot; 1751.7(b) &quot;Each individual involved in the preparation of sterile drug preparations must first successfully demonstrate competency by successfully performing aseptic media-fill tests before being allowed to prepare sterile drug preparations. The media fill testing process shall be as complicated as the most complex manipulations performed by staff and contain the same amount or greater of volume transferred during the compounding process...&quot; Media-Fill Test Procedure—This test or an equivalent test is performed at least annually under conditions that closely simulate the most challenging or stressful conditions encountered during compounding.</td>
</tr>
<tr>
<td>1735.1(w)</td>
<td>Lynn Paulsen</td>
<td>Does it include topical. Definition needs to be further defined. Okay with Irrigation, Ophthalmic, Inhalation, Through the skin.</td>
</tr>
<tr>
<td>1735.1(y)</td>
<td>Lynn Paulsen</td>
<td>Potency USP 797 requirements of +/- 10% is not addressing the dilution of commercial product. They are addressing making a product from chemical ingredients. Need to define dilutions separately because of titrations. Commercial products are already +/-10% and then are diluted the resulting diluted product will exceed +/-10%. USP standard is for USP products and is different than diluting products.</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1735.1(y)</td>
<td>Jeannette Hanni</td>
<td>Exempt when final product is the result of dilutions. Example: 1g in 250cc bag. The bag is already +/- 10% (USP Standard). Adding the 1g will change the potency further.</td>
</tr>
</tbody>
</table>
| 1735.1(y)    | Doug O'Brien  
Kaiser Permanente | Recommendation: "Potency" means active ingredient strength within +/- 10% of the labeled amount for sterile commercial products.  
Rationale: Sterile commercial products are already at +/- 10% so unable to meet this requirement for sterile compounded preparations in which multiple commercial products are utilized to compound the final preparation. |
| 1735.1(y)    | BJ Bartleson  
California Hospital Association | With the definition as stated, the potency definition will be impossible to meet. For example: a typically compounded product is Vancomycin 1 gram injected into a 250 ml bag of normal saline. The 250 ml bag is a commercially available product purchased from manufacturers who may add as much as 25 ml's of overfill to their bags, which would result in a volume of 275 ml's. The 1 gram Vancomycin vial from the manufacturer is reconstituted with 20 ml's of sterile water and added to the 275 bag of saline, equaling a final volume of 295 ml's resulting in a final concentration of 3.39 mg/ml (1000mg/295ml), the labeled potency of the 1g/250ml piggyback would result in a discrepancy of 15% well above the +/-10% allowance. These are simple compounds from standard manufacturer ingredients and will result in a continuous state of non-compliance with the potency range as defined in the proposed regulations. |
| 1735.1(y)    | Bruce Lepley  
Community Regional Pharmacy | Reason for Concern: USP 797 only describes potency in terms of ensuring potency by monitoring controlled storage areas. In addition, considering the many drugs that could be compounded (biosimilars, immune mediators, blood derivatives, etc) it may be too arbitrary to put such a hard limit on this definition.  
Solution: Remove section that defines “potency” altogether. |
| 1735.1(ab)   | Amy Gutierrez | At today's sterile compounding training, we discussed the use of sterile compounding robots, which have become popular in California. As we don't have reference to robots in our regs, I am proposing a modification to 1735.1 (ab) to the following (changes in bold):  
(ab) "Primary Engineering Control (PEC)" means a device that provides an ISO Class 5 or better environment through the use of unidirectional HEPA-filtered first air for the exposure of critical sites when compounding sterile preparations. Examples of PEC devices include, but are not limited to, laminar airflow workbenches, biological safety cabinets, **sterile compounding automated robots**, compounding aseptic isolators, and compounding aseptic containment isolators. |
| 1735.1(ae)   | Marie Cottman  
Pacific Compounding Pharmacy | Comments: "...the absence of inactive ingredients other than those listed on the master formula record." There are times when the compounding record inactive ingredients will slightly deviate from the master formula record. For instance, if the sweetener stevia is outdated, we may use (one time only) acesulfame as the sweetener. Or we may use Ora Plus sugar free in place of Ora Plus, if there is a backorder from our wholesaler for the Ora Plus listed in the master formula record. When these rare changes take place, compounders **SHOULD MAKE NOTE ON THE COMPOUNDING RECORD**, but should not be required to modify the master formula record. Please note: these are rare exceptions.  
Recommendation: Change "master formula record" to "compounding record." |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1735.1(af)   | Doug O'Brien
Kaiser Permanente | Recommendation: Allow compounding of hazardous drugs in a segregated compounding area within a CACI by removing the language “non-hazardous”. The applicable sentence would read, “The segregated sterile compounding area shall be restricted to preparing non-hazardous sterile to sterile compounded preparations.”  
Rationale: The USP 797 definition of a Segregated compounding area is "a designated space, either a demarcated area or room, that is restricted to preparing low-risk level CSPs with 12 hour or less BUD". USP 797 section Placement of Primary Engineering Controls allows placement of a CACI (used for hazardous drug compounding) in less clean than ISO Class 7 areas if the following conditions are met:  
- The isolator shall provide isolation from the room and maintain ISO Class 5 during the dynamic operating conditions, including transferring ingredients, components, and devices into and out of the isolator and during preparation of CSPs  
- Particle counts sampled approximately 6 to 12 inches upstream of the critical exposure site shall maintain ISO Class 5 levels during compounding operations  
- Not more than 3520 particles per m3 shall be counted during material transfer, with the particle count probe located as near to the transfer door as possible without obstructing the transfer. |
| 1735.1(af)   | Bruce Lepley
Community Regional Pharmacy | 1. Reason for Concern: Many hospitals have established pharmacy satellites nearby patient care areas to serve our most vulnerable patients (e.g. Intensive Care Units). The central pharmacy is too far from these patient care areas and the pharmacy satellites provide a venue to provide patient care that is closer to the patients. These pharmacy satellites are one room that provides a place for the pharmacy to perform order verification, drug storage, and drug preparation. Many of the pharmacy satellites have very limited room, thus the pharmacy will place compounding aseptic containment isolators (CACIs) which are enclosed to the surrounding environment and should have evidence from the manufacturer that they meet USP chapter 797 and Controlled Environment Testing Association (CETA) requirements. If one were to believe that this is an unverified study then one would have to question most of the conclusions derived from USP 797 as many of the conclusions taken from there are not based on “randomized controlled trials”.  
2. We believe that we can remove the 3 foot no sink/drain requirement when CACIs are used to support pharmacy satellites. The alternative would be to close these pharmacy satellites that do not have the room to abide by the 3 foot no sink/drain rule which is not consistent with a patient centered care model.  
Solution: Make an exception that if the ISO Class 5 PEC is a CACI, that the three foot sink/drain rule does not apply while maintaining that sinks and drains should not be placed in a buffer area or in ISO class 7 or better. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Recommendation/ Comments:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1735.1(af)</td>
<td>Anonymous</td>
<td>While some PEG may gain benefit by having the 3 foot perimeter, other PEG’s such as barrier isolators does not have such requirement, yet for other poorly designed PEGs, the 3 foot may still not be enough. Therefore, the size of the demarcated area should be according to PEG’s mfg recommendation/specification, rather than a fixed 3 foot for all. I checked with my barrier isolator mfg, and there is a list of location requirements and specifications, but mfg does not require a 3 foot clearance. Having such clearance provides no additional safety margin. Barrier isolator is already a self-contained “clean room” and “ante room”. To require anther 3 foot clearance around it is like saying there needs to be 3 foot clearance outside the clean room. The fiscal impact of this regulation is much more than anticipated, and in some cases, there is no safety margin gained. Many smaller hospitals and satellite pharmacies have recently undergone renovations to be in compliance with the current regulation. Most isolators are 4 to 5 foot wide. Requiring another 3 foot perimeter means the room has to be at least 10 foot. Smaller hospital pharmacies and satellite pharmacies simply do not have the space. Passing this regulation would mean more renovations and construction, which may interrupt patient care and reduce safety margin.</td>
</tr>
<tr>
<td>1735.2</td>
<td>Lynn Paulsen</td>
<td>Some Hospitals have not changed from expiration date to BUDs and the change cannot be done overnight due to the training of thousands of nurses and staff. An implementation schedule over the next year or two would be necessary.</td>
</tr>
<tr>
<td>1735.2(c)(1)</td>
<td>Doug O’Brien</td>
<td>This proposed regulatory language is vague and does not reflect either California statutory authority nor federal case law. The term “fair market value” cannot practically apply to pharmacy-compounded items because there are no published prices that compounding pharmacies can use to determine that fair market value, unlike resources that are available for products approved for distribution in interstate commerce by the FDA. Compounding pharmacies are prohibited by anti-trust law from contacting other compounding pharmacies to discuss established prices. Further, there is no reference material available to even determine which competing pharmacies are compounding and distributing the exact same compounded products. Each compounding pharmacy has to determine its own pricing based on its costs, risk calculations, and marketing strategy. Generally speaking the costs per unit compounded by a pharmacy will be substantially higher than the market value of FDA approved similar products because of a lack of “economy of scale” vs manufacturing facilities. Further, Calif. Business and Professions Code Section 4380 establishes in California statutory law recognition of two federal court cases that allow non-profit institutions to acquire products at prices generally unavailable to for-profit organizations and use of those products for the treatment of specified patients related to the not-for-profit institutions, e.g. certain hospitals and health plans. Such products are often supplied to physicians in medical office environments at no charge for treatment of such patients. This includes pharmacy-compounded products supplied to prescribers for prescriber office use under Business and Professions Code Section 4052(a)(1).</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| 1735.2(c)(1) | Brian Warren  
California Pharmacist Association  
(Also commented on at hearing by Tony Park) | (1) Is ordered by the prescriber or the prescriber’s agent and paid for by the prescriber at a price that fairly reflects the fair market value of each drug preparation, using a purchase order or other documentation received by the pharmacy prior to furnishing that lists the number of patients seen or to be seen in the prescriber’s office for whom the drug is needed or anticipated, and the quantity for each patient that is sufficient for either office administration or application to patients in the prescriber’s office, or for distribution of not more than or furnishing of a 72-hour supply to the prescriber’s patients, as estimated by the prescriber; and |
|              |           | The proposed requirement that physician office use compounded preparations be sold “at a price that fairly reflects the fair market value of each drug preparation” is arbitrary, difficult to enforce, and beyond the scope of the Board’s mandate of protection of the public health and safety. In no other statute or regulation does the Board attempt to regulate the prices or pricing of prescription drugs dispensed by pharmacists. |
|              |           | The Board’s Initial Statement of Reasons states that the changes to Section 1735.2 are intended to ensure that compounding regulations reflect current statutory provisions and are in alignment with USP 37 <797>. does not specify the purpose for this change. |
| 1735.2(d)(3) | Bruce Lepley  
Community Regional Pharmacy | Reason for Concern: Many medications that are in short supply in “real time” may not be on the ASHP or FDA drug shortage list in a timely manner (e.g. most recent example IV Protonix January 2015). ASHP and FDA recognize that this may happen as they have to rely on clear communications to them for their source of information. |
|              |           | Solution: Add “Manufacturer, Wholesaler, and/or Distributor acknowledge and provide documentation that the drug is in short supply.” |
| 1735.2(d)(3) | Michael Tou  
Providence Health | (d) No pharmacy or pharmacist shall compound a sterile drug preparation that:  
(3) is a copy or essentially a copy of one or more commercially available compendial drug products…  
The current wording of 1735.2(d)(3) prohibits pharmacies from diluting their own vancomycin 1 gram as in the example above because it is “essentially a copy” of a commercially-available drug product.  
The implications of this restriction would be far-reaching:  
- Costs to pharmacies and costs to treat patients would be exponentially more expensive if pharmacies cannot compound their own sterile IVPBs even when a commercial premix product is available.  
- Manufacturers who produce premixed products would corner the market and profit from this regulation. Generic drug manufacturers that produce FDA approved drug vials and solutions to be used for sterile compounding will suffer.  
- Drug shortages will worsen since premix sterile dilution products are the only ones that could be used in the state. It will drive the demand for these premix IVPB products and the lone manufacturers would not be able to meet the needs of pharmacies.  
- In the event of a drug recall of a premix commercially-available product, pharmacies may not be able to perform compounding unless the drug appears on the ASHP or FDA drug shortage list. If the rest of the country is not restricting pharmacies from compounding copies or essential copies of commercially-available drug products, no shortage will be listed.  
Even TPN (total parenteral nutrition) is available commercially as premixed bags. TPN contents are usually customized to meet the nutrition, caloric, and electrolyte needs for the patient. Some of the TPN formulas are available as premixed bags from the manufacturers. The language in this section would prohibit the pharmacy from preparing a TPN formula that matches those available as TPN products. It would not be feasible for pharmacies to stock every commercially available TPN bag in order to provide the TPN needs for every patient. Being able to compound the TPN using sterile products is a necessity. |
|              |           | Continued on Next Row:
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1735.2(d)(3) | Michael Tou Providence Health | Continued from Previous Row:  

We agree that preparation of sterile drug products that are copies or essentially copies of commercially-available drug products should be prohibited when those processes involve utilizing non-sterile ingredients to prepare sterile drug products unless there is a documented current drug shortage and appropriate safety measures and procedures are followed. For example, preparation of calcium chloride sterile solution for injection utilizing non-sterile calcium powder.  

Non-sterile compounding of commercially-available drugs should be permitted for non-parenteral administration. For example, caffeine citrate oral solution is commercially available in a ready-to-administer solution but is also safely compounded utilizing caffeine powder, citric acid powder, and water to prepare essentially the same drug product with the strength/concentration and formulation. Stability studies have been done on the extemporaneous compounded formulation from these powders and have been shown to be safe and effective for treating patients. |
| 1735.2(e)(5) | Bruce Lepley Community Regional Pharmacy | Reason for Concern: The language may be too broad. We understand it would be hard to place exactly what is required considering all of the entities that will be using these regulations, but perhaps we can narrow the language by inserting phrases such as “essential compounding steps”. This will help facilitate pharmacies to receive approval during the policy approving process who are based in institutions with multidisciplinary committees by leaving out unwanted minutia of the compounding process in policies and procedures.  

Solution: Reword section to state “Specific and essential compounding steps used to prepare the drug” |
| 1735.3(a)(1) | Marie Cottman Pacific Compounding Pharmacy | Comment: The description of this section warrants naming the document that will contain all of this information (a)(1) through (a)(9). In practice it is referred to as a compounding log or formula log.  

Recommendation: Clarify the reference term for the document that is described in section 1735.3(a)1 as a “compounding formula record” or “compounding record” or “compounding work sheets” as referenced in 1751.3 (b)(1).  

Question: Can the master formula record be contained in electronic format? Though the master formula record is critical to consistency from batch to batch (or lot to lot) of the same compounded preparation, it does not contain any information that would not be included on the compounding record (which is much more specific to what and how a preparation was made).  

Recommendation: Clarify that the master formula record must be available but does not have to be maintained WITH the compounding record. |
| 1735.3(a)(5) | Marie Cottman Pacific Compounding Pharmacy | Comments: The term “component” is inconsistent with language in section 1735.2 e1 and 1735.2 e4 which reference active ingredients and inactive ingredients respectively.  

Recommendation: Change the term “component” to “ingredient.” |
| 1735.3(a)(6) | Marie Cottman Pacific Compounding Pharmacy | Comments: The term “component” is inconsistent with language in section 1735.2 e1 and 1735.2 e4 which reference active ingredients and inactive ingredients respectively.  

Recommendation: Change the term “component” to “ingredient.” |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1735.3(a)(6) | Doug O'Brien  
Kaiser Permanente | Recommendation: Include ambulatory oncology clinic pharmacies in the seventy-two (72) hour exception language, in a manner similar to inpatient pharmacies.  
Rationale: Ambulatory oncology clinic pharmacies compound preparations in a similar manner to inpatient pharmacies. |
| 1735.4(c) | Brian Warren  
California Pharmacist Association | (c) Drug products prepared into unit-dose containers that are too small or otherwise impractical for full compliance with subdivisions (a) and (b) shall be labeled with at least the name of the compounding pharmacy and dispensing pharmacy, if different, the name(s) of the active ingredient(s), concentration or strength, volume or weight of the preparation, pharmacy reference or lot number, and expiration beyond use date and shall not be subject to minimum font size requirements.  
The Board is proposing to add the name of the compounding pharmacy and dispensing pharmacy to the text of what must be included on unit-dose containers that are too small or otherwise impractical for full compliance with all labelling requirements. Adding this additional text to unit-dose labels may place space limitations on those labels, thereby necessitating that labels be printed in a smaller font size. This modification is within the scope of these proposed regulations because the Board is adding additional text to be included on the label. |
| 1735.5(a) | Brian Warren  
California Pharmacist Association  
(Also commented on at hearing by Tony Park) | (a) Any pharmacy engaged in compounding shall maintain a written policies and procedures manual for compounding that establishes procurement procedures, methodologies for the formulation and compounding of drugs, facilities and equipment cleaning, maintenance, operation, and other standard operating procedures related to compounding. Any material failure to follow the pharmacy's written policies and procedures may constitute a basis for disciplinary action.  
Regulations should give the Board the authority to take disciplinary action, they should not require that the board take disciplinary action. Additionally, disciplinary action should be taken for material failure to follow policies and procedures, not for any deviations irrelevant to the compounding of drugs. |
| 1735.6(d) | Brian Warren  
California Pharmacist Association  
(Also commented on at hearing by Tony Park) | (d) **(1)** Any pharmacy engaged in any hazardous drug compounding shall maintain written documentation regarding appropriate cleaning of facilities and equipment to prevent cross-contamination with non-hazardous drugs.  
**(2)** Any pharmacy engaged in any hazardous drug compounding shall perform such compounding with the use of a powder containment hood.  
All pharmacies compounding hazardous drugs should use powder containments hoods to ensure pharmacist and pharmacy technician safety. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1735.8(c) | **Doug O’Brien**  
Kaiser Permanente | Recommendation: “The quality assurance plan shall include written standards for qualitative and quantitative analysis of compounded drug preparations to ensure integrity, potency, quality, and labeled strength, of compounded drug preparations. The criteria by which preparations would be tested for potency, quantitative analysis, and labeled strength analysis shall be described in the quality assurance plan. All qualitative and quantitative analysis reports for compounded drug preparations shall be retained by the pharmacy and maintained along with the compounding record and master formula.”  
Rationale: This language could be interpreted to require that quantitative and qualitative analysis be performed on all compounded products regardless of cost, availability of the actual assay, or scientific validity. It has been our experience that some Board of Pharmacy inspectors have interpreted this language to require end product potency testing of all pharmacy-compounded products. KP. Many pharmacy professionals disagree with those requirements as they are inconsistent with the intent and provisions of the regulation 1735, et. seq. Pharmacies are compliant with 1735.8(c) if they have a PLAN that includes the elements mentioned above. Quantitative and qualitative laboratory type testing is not required unless specified for each product in our policies and procedures generally or by category - or in the Master Formula for a particular product. Test records of tests only have to be retained if such test was done either as a matter of policy or pursuant to an investigation after the raising of a quality concern for particular compounded preparation or a batch of a compounded preparation.  
Please see the detailed testimony from KP regarding this issue which was presented to the BOP Enforcement and Compounding Committee on September 16, 2014.  
The Board’s proposed regulation language perpetuates substantial confusion and inhibits compliance and enforcement. As proposed the regulation would add major costs to hospital and other pharmacy-compounding thus adversely affecting the cost and affordability for therapeutic availability, the effectiveness and safety of patient care with scientific justification. |
| 1735.8(e) | **Douglas Barcon**  
Barcon & Associates | Change “or” to “and”, so the QA plan includes responding to out-of-range temperatures in the pharmacy and patient care areas versus one or the other. |
| 1751(b)(3) | **Brian Warren**  
California Pharmacist Association | (6) (3) A sink shall be included in accordance with Section 1250.4 of Title 24, Part 2, Chapter 12, of the California Code of Regulations. Sinks and drains shall not be present in any ISO Class 7 or better buffer area or cleanroom, nor in a segregated sterile compounding area within three feet of an ISO Class 5 or better PEC, with the exception of emergency eye rinsing stations. A sink may be located in an ante-area.  
This comment was submitted during the last rulemaking and had been accepted, though was not incorporated into this rulemaking. Additionally, the definition of a segregated sterile compounding area in Section 1735.1(af) includes the exception for emergency eye-rinsing stations. The emergency eye-rinsing station should be included here for consistency. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1751(b)(3)</td>
<td>Bruce Lepley Community Regional Pharmacy</td>
<td>Reason for Concern: Many hospitals have established pharmacy satellites nearby patient care areas to serve our most vulnerable patients (e.g. Intensive Care Units). The central pharmacy is too far from these patient care areas and the pharmacy satellites provide a venue to provide patient care that is closer to the patients. These pharmacy satellites are one room that provides a place for the pharmacy to perform order verification, drug storage, and drug preparation. Many of the pharmacy satellites have very limited room, thus the pharmacy will place compounding aseptic containment isolators (CACIs) which are enclosed to the surrounding environment and should have evidence from the manufacturer that they meet USP chapter 797 and Controlled Environment Testing Association (CETA) requirements. If one were to believe that this is an unverified study then one would have to question most of the conclusions derived from USP 797 as many of the conclusions taken from there are not based on “randomized controlled trials”. We believe that we can remove the 3 foot no sink/drain requirement when CACIs are used to support pharmacy satellites. The alternative would be to close these pharmacy satellites that do not have the room to abide by the 3 foot no sink/drain rule which is not consistent with a patient centered care model. Solution: Make an exception that if the ISO Class 5 PEC is a CACI, that the three foot sink/drain rule does not apply while maintaining that sinks and drains should not be placed in a buffer area or in ISO class 7 or better.</td>
</tr>
<tr>
<td>1751(b)(3)</td>
<td>Bruce Lepley Community Regional Pharmacy</td>
<td>Reason for Concern: In the March 2015 BOP Draft (5th Draft) there was verbiage that stated “with the exception of emergency eye-rinsing stations”. We believe that this exception is the safest for the employees preparing sterile products and complies with NIOSH Guidelines. Solution: Reinsert the exception to include emergency eye-rinsing stations in these areas in addition to the above solution (Number 2) to allow CACI’s be an exception also.</td>
</tr>
</tbody>
</table>
| 1751.1       | Julie Brosz | (a) In addition to the records required by section 1735.3, any pharmacy engaged in any compounding of sterile drug preparations, shall make and keep the following records within the pharmacy: 
(1) Documents evidencing training and competency evaluations of employees  Sterile Compounding Personnel in sterile drug preparation policies and procedures. 
(2) Results of hand hygiene and garbing assessments of Sterile Compounding Personnel with integrated gloved fingertip testing. 
(3) Results of assessments of personnel  Sterile Compounding Personnel for aseptic techniques including results of media-fill tests and gloved fingertip testing performed in association with media-fill tests. References to personnel made more specific to indicate those actually engaged in sterile compounding in the controlled environment. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1751.1</td>
<td>Michael Tou</td>
<td>Providence Health</td>
</tr>
<tr>
<td></td>
<td>Add to Section 1751.1 definition: Compendial drugs are drug products or preparations for which there is a monograph provided in an official compendia (e.g. United States Pharmacopeia, National Formulary, or Homeopathic Pharmacopeia) recognized by the Food, Drug, and Cosmetic Act. The compendium sets forth standards for the strength, quality and purity of the drug product. -OR- Add: (4) Compounding (reconstitution and/or dilution) of FDA approved drug products is excluded from this restriction. If the intent of the board was to prevent what would essentially be the manufacturing of copies of compendial drug products by pharmacies, the language needs to be modified to clearly indicate this. Dilution/reconstitution and compounding of drug products using FDA-approved drug products should be exempted. Providence recommends changing the language to allow compounding (reconstitution and/or dilution) using FDA-approved drug products. The proposed language seen in the center column can be interpreted to prohibit dilution of FDA-approved drug products per FDA instructions, if there is a pre-diluted (premix) drug product commercially available. As defined in 1735.1(l) “copy or essentially a copy” of a commercially-available drug product would include all diluted intravenous infusion bags, including IV piggy backs or IVPBs that are available as premix bags from the manufacturer. Some brand name manufacturers have FDA-approved “premixed” IV bags that are ready-to-administer and are virtually the same preparation as other FDA-approved drug vials that are diluted prior to administration per the FDA-approved package insert instructions. Premix IV bags would fall into the definition since they are commercially-available drug products. Continued in Next Row:</td>
<td></td>
</tr>
<tr>
<td>1751.1</td>
<td>Michael Tou</td>
<td>Providence Health</td>
</tr>
<tr>
<td></td>
<td>Continued from Previous Row: For example: Vancomycin is available as a frozen premix IVPB bag in different strengths that are the most commonly prescribed (e.g., 1 gram). The frozen premix bag is thawed and administered to the patient without further dilution. Vancomycin is more commonly available as a sterile powder vial that requires further dilution (per FDA-approved package insert instructions and labeling) into an IV solution bag prior to administration. Vancomycin premix IVB is 1 gram of vancomycin in D5W 200ml. Pharmacies can typically prepare that same IVPB bag of 1 gram of vancomycin in D5W 200ml using a vancomycin sterile powder vial, reconstituting it as directed with sterile water and further diluting the 1 gram amount into an IVPB bag of D5W solution. The resulting preparations are the same: same active and inactive drug and diluent, same dose, same volume. The cost of utilizing the sterile powder vial of vancomycin and the plain D5W IV solution bag is less expensive than purchasing the vancomycin bag that is already diluted and ready-to-administer.</td>
<td></td>
</tr>
<tr>
<td>1751.1(a)(5)</td>
<td>Bruce Lepley</td>
<td>Community Regional Pharmacy</td>
</tr>
<tr>
<td></td>
<td>Reason for Concern: In the March 2015 BOP Draft (5th Draft) there was verbiage that stated the recordation was for “sterile compounded drug preparations”. The new verbiage removed the word “sterile” implying that all compounded drug preparations required this documentation which in not the focus of the intended section. Solution: Reinsert the verbiage “sterile” in the compounded drug preparation requirement to maintain consistent with the section.</td>
<td></td>
</tr>
<tr>
<td>1751.1(a)(5)(c)</td>
<td>Douglas Barcon</td>
<td>Barcon &amp; Associates</td>
</tr>
<tr>
<td></td>
<td>There is no definition of “controlled freezer temperature” in USP general chapter 659 Packaging and Storage Requirements, USP 797, or the general notices in USP-37 NF-32. Suggest deletion of the word “controlled” as in 1735.1 (j) comment.</td>
<td></td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1751.1(a)(7)</td>
<td>Bruce Lepley Community Regional Pharmacy</td>
<td>Reason for Concern: USP 797 allows for at least daily documentation or by using a continuous recording device. We would like to continue to allow the use of a continuous recording device as an alternative which would also give the facility better &quot;real time&quot; data. Solution: Reword the section to state &quot;Documents indicating daily recordation or by continuous recording device of air pressure differentials…&quot;</td>
</tr>
<tr>
<td>1751.1(a)(10)</td>
<td>Marie Cottman Pacific Compounding Pharmacy</td>
<td>Comments: The terms &quot;preparation work sheet&quot; and &quot;master work sheet&quot; are inconsistent with compounding record and master formula record. Recommendation: Be consistent in the terms for a master formula record (well prescribed in section 1735.3) and the compounding record (see comments regarding 1735.3 (a)(1).</td>
</tr>
<tr>
<td>1751.2(b)</td>
<td>Marie Cottman Pacific Compounding Pharmacy</td>
<td>Comments: This can become a very long list depending on the formulation. Why do we need to include the inactive ingredients as well as the active ingredients when this is not done for non-sterile compounding? Do you want us to list on the label how much hydrochloric acid or sodium hydroxide we added to get to the right pH? How would this be indicated correctly? For instance, we start with a 1% HCl solution and add 3 drops to a final volume of 15 ml… the math to determine the final strength is doable (0.01%), but may vary from batch to batch and will have no relevance to the end user. Recommendation: Please provide clarification on implementation specific to inactive ingredients.</td>
</tr>
<tr>
<td>1751.2(b)</td>
<td>Michael Tou Providence Health</td>
<td>Name and strength, volume or weight of each active ingredient contained in the sterile drug preparation. Request clarification or guidance on this requirement for &quot;each ingredient:&quot; - Are inactive ingredients required on the label? - If inactive ingredients are required on the label, please exclude inactive agents used to reconstitute a powder vial (e.g., sterile water) that will be further diluted in solution for the sterile compounded drug preparation. If sterile water appears on the label of the compounded sterile drug preparation, it would be confusing for those reading the label since the sterile water for reconstitution is not part of the prescription or drug order and of no clinical significance to the patient. - Providence recommends that each active ingredient be required on the label and the only inactive ingredient(s) required should be the final diluent solution used to dilute the sterile compounded preparation’s active ingredient. This would be consistent with the modified language proposed in 1735.1(ae). 1735.1(ae) implies that only active ingredients are listed on the label and inactive ingredients do not have to be listed on the label because they are in the compounding log: (d)(w)(ae) &quot;Quality&quot; means the absence of harmful levels of contaminants, including filth, putrid, or decomposed substances, and the absence of active ingredients other than those listed on the label, and the absence of inactive ingredients other than those listed noted on the compounding log label. - 1735.4(c) requires the name(s) of the active ingredient(s) only. It does not require the inactive ingredients as well. - Sterile compounded drug preparations are prepared in single-dose containers or unit-dose containers and each ingredient would not fit on the label if inactive ingredients were also required.</td>
</tr>
</tbody>
</table>

Continued on next Row:
**Code Section** | **Commenter** | **Comment**
--- | --- | ---
1751.2(b) | Michael Tou (Providence Health) | *Continue from Previous Row:*
Providence also recommends changing the requirement of the concentration on the label to include the strength, volume or weight of the ingredient(s).
- This would be consistent with labeling requirements from 1735.4(c) that require the name of the active ingredient(s), strength, volume or weight of the preparation.
- B&PC 4076 requires only the strength of the drug.
- If the active ingredient dose or strength is on the label and the final volume of the diluent is also on the label, then the concentration should not be required. Most drugs that are sterile compounded preparations are prescribed, ordered and prepared as the drug dose only (not the concentration). For example, prescribers order Vancomycin 1 gram IV once. The current labels typically will state the drug name, dose, and volume and name of the appropriate diluent: “Vancomycin 1 gram in 200ml of Normal Saline.” This is much more clear and accurate than if the label were to state vancomycin 5mg/ml which is the concentration.

1751.3 | Julie Brosz (Providence Health) | (a) Any pharmacy engaged in compounding sterile drug preparations shall maintain a written policies and procedures manual for compounding that includes, in addition to the elements required by section 1735.5, written policies and procedures regarding the following:
...
(12) Orientation, training, and competency evaluation of *staff* Sterile Compounding Personnel in all aspects of the preparation of sterile drug preparations including didactic training and knowledge/competency assessments that include at minimum: hand hygiene and garbing; decontamination (where applicable); cleaning and disinfection of controlled compounding areas; and proper aseptic technique.
The original word “staff” may be subject to misinterpretation and lead to a universal practical testing requirement in a pharmacy.
Additionally, in various sections of the proposed regulations, staff are referred to as “personnel,” “staff,” and “employees.” We believe these terms are intended to refer to the same individuals and recommend using consistent terminology.

1751.3 | Lynn Paulsen | USP 797 requires indentifying CFUs to genesis level to trigger action. This is because individual bacteria of a specific type may trigger action; while others may not require immediate action until 10 or more CFUs are identified.

1751.3(a) | Marie Cottman (Pacific Compounding Pharmacy) | Comments: The items in this list are fine, but the order of this list is awkward and feels like someone just threw a bunch of ideas down during a brainstorming session.
Recommendation: Sort this list by importance, sequence of events (Garbing and Gloving procedure should occur before fingertip testing), or alphabetically as done for definitions.

1751.3(b)(1) | Marie Cottman (Pacific Compounding Pharmacy) | Comments: The term “compounding work sheets” is inconsistent with language in several other sections.
Recommendation: Change “compounding work sheets” to “compounding formula record.”

1751.4(d) | Eric and Kate | Comment: Cleaning poorly written and misleading. Recommend: All ISO Class 5 surfaces, work tables, carts, and the floor in the buffer area will be cleaned at least daily (at the beginning or end of the compounding day or shift) using a germicidal detergent and water. Surfaces in the ISO Class 5 PEC shall be disinfected using a suitable sterile agent (e.g. sterile IPA) frequently, including (1) at the beginning of each shift (2) before and after each lot (3) after each spill; and (4) when surface contamination is known or suspected.
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1751.4(d)    | Doug O'Brien  
Kaiser Permanente | Consider a typical scenario in a clean room in a hospital pharmacy. During a 15-minute period of compounding operations, pharmacy personnel could compound four doses of azithromycin 500 mg/250mL dextrose 5% for four different patients, two doses of famotidine 40 mg in 250mL dextrose 5% 250mL for one patient, and five doses of furosemide 100mg/100mL dextrose 5% for five different patients. Under the definition of “lot”, pharmacy personnel would be required to clean and disinfect the ISO Class 5 PEC before and after each lot – four times in 15 minutes. If one considers the number of lots that would be compounded in four hours, the PECs would need to be cleaned and disinfected 50 to 60 times. We therefore recommend that 1751.4(d)(2) be deleted. Subsections 1751.4(d)(1), 1751.4(d)(3), and 1751.4(d)(4) are sufficient. Proposed language adds confusion and inhibits compliance and enforcement. Unnecessary cleaning delays product provision and increases costs that will adversely affect patient access to care. |
| 1751.4(d)    | William Stuart  
Hartley Medical | Recommend:  
(d) Cleaning and disinfecting surfaces in the ISO Class 5 PEC shall occur frequently, including:  
(1) At the beginning of each shift;  
(2) Before and after each lot;  
(3) Not longer than 30 minutes following the previous surface disinfection when ongoing compounding activities are occurring;  
(4) After each spill;  
(5) When surface contamination is known or suspected.  
Rationale:  
We recommend remaining consistent with USP <797> guidelines.  
Site: ISO Class 5 Primary Engineering Control  
Minimum Frequency: “At the beginning of each shift, before each batch, not longer than 30 minutes following the previous surface disinfection when ongoing compounding activities are occurring, after spills, and when surface contamination is known or suspected”  
(Source: Chapter <797>, Table 3. Minimum Frequency of Cleaning and Disinfecting Compounding Areas, USP 38-NF 33, February 2015) |
| 1751.4(d)    | BJ Bartleson  
California Hospital Association | No change in wording proposed- Simple recommendation to changing the numbering from 1751.4 (d) to 1754.4 (d)(1) for entire section so the below can be added. |
| 1751.4(d)(2) | BJ Bartleson  
California Hospital Association | Insert new language, “alternate cleaning schedules may be submitted to the Board, as in the case of fully automated IV robots”  
A contained robotic compounding is possible contaminated by the cleaning process. An alternative schedule such as mini clean daily, full clean weekly, etc., should be appended to the self-assessment form with documentation for the first submission. |
<p>| 1751.4(d) &amp; (e) | Lynn Paulsen | Add language for self cleaning robot. A self-contained robot is not cleaned after every prep. Contamination comes from hands and arms. Mini-clean once a day, full clean once a week. Manufacturer instructions. Board can review alternative methods for approval. The cleaning requirements as is would eliminate the ability to use robotics in California. |</p>
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1751.4(d)(2)</td>
<td>Rheta Sandoval</td>
<td>Cleaning AND disinfecting surfaces of the ISO Class 5 PEC before and after each lot (per the proposed definition in 1735(t)) may not be feasible depending on the scale of operations. There could be interference with timely medication preparation and dispensing in the hospital setting and significant operational impacts. For hospital pharmacies that are preparing upwards of 60,000 dosage units annually, 5 minutes or more spent cleaning surfaces followed by disinfecting surfaces in the ISO 5 PEC before and after compounding each “lot” would have a definite impact on operations and costs. USP and ASHP Guidelines on Compounding Sterile Preparations requires cleaning and disinfecting before each batch, with a “batch” defined differently than the BOPs proposed definition of “lot”. Adopting USP 797’s minimum frequency of cleaning and disinfecting the PEC with the term “batch” interchanged with “lot” could result in a regulation that would be difficult if not impossible for some facilities to comply with depending on compounding volume. The USP intent of the cleaning the PEC with a germicidal detergent is that it only needs to be done once a day (end of the compounding day or the beginning) (Personal Communication. Eric S. Kastango, MBA, RPh, FASHP. 3/25/15). The work areas need to be disinfected with sterile IPA or another suitable agent before each batch (Personal Communication. Eric S. Kastango, MBA, RPh, FASHP. 3/25/15). In the “Cleaning and Disinfecting the Compounding Area” section of USP &lt;797&gt;, it states “When the surface to be disinfected has heavy soiling, a cleaning step is recommended prior to the application of the disinfectant”. In light of these points and keeping the general principle of cleaning in mind, that “all surfaces need to be visibly wetted, but not dripping, and the agent must be allowed to air dry” (K. Douglas, ES. Kastango. Requirements and Best Practices for Sanitizing Engineering Controls, ppmag, September 2013), the proposed regulation 1751.4(d)(2) is not feasible across all pharmacy sterile compounding settings. Please consider the following modification: 1. Revise 1751.4(d)(2) to read: before and after each lot (at minimum, disinfection);</td>
</tr>
<tr>
<td>1751.4(d)(2)</td>
<td>Bruce Lepley</td>
<td>Reason for Concern: The most recent USP 797 regulations state that cleaning of the ISO 5 PEC should occur at the beginning of each work shift, before each batch (USP 797 only uses the word batch in referencing high-risk compounding) preparation is started, every 30 minutes during continuous compounding periods of individual CSPs, when there are spills, and when surface contamination is known or suspected from procedural breaches. With the new proposed definition of “lot,” interruption of workflow of hospital compounding in order to clean before and after each lot may impact the timeliness of medication delivery to patient and could introduce potential for medication errors. Solution: Remove “before and after each lot” and replace with “every 30 minutes during continuous compounding.”</td>
</tr>
<tr>
<td>1751.4(d)(4)</td>
<td>Marie Cottman</td>
<td>Comments: We do not access our cleanroom on a daily basis, but use it approximately one or two times per week. As “daily” is defined in section 1735.1(m) as every day a pharmacy is operating, this regulation would require that my staff enter and clean the counters, work surfaces and floors even on days that the facility is not used! This, in my opinion, would increase the risk of contamination by excessive entry that is not necessary. Recommendation: Clarify the regulation by changing “daily” to “on each day of use.”</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1751.4(e)</td>
<td>BJ Bartleson California Hospital Association</td>
<td>“Outside the PEC, counters, cleanable work and table surfaces and floors shall be cleaned with germicidal detergent and rinsed with water daily. Walls, ceilings, storage shelving, and stools shall be cleaned with a germicidal detergent and rinsed with water monthly.” CHA has concerns that the definitions of disinfectants and germicidal detergent overlap significantly. Disinfection of walls, ceilings, stools and floors as separate and distinct from the germicidal detergent is not supported by evidence.</td>
</tr>
<tr>
<td>1751.4(e)</td>
<td>Michael Tou Providence Health</td>
<td>Counters, and cleanable work surfaces and floors shall be cleaned with a germicidal detergent and water and disinfected with a suitable agent daily. Floors in the buffer or clean area, ante-area, and segregated compounding area are cleaned by mopping with a cleaning and disinfecting agent once daily at a time when no aseptic operations are in progress. Providence recommends adding USP 797 wording for floor cleaning requirements. The current proposed wording of this section requires a three-step cleaning for floors which USP 797 does not require (a germicidal detergent and water and a disinfecting agent). If a single cleaning agent both cleans and disinfects it can be used alone according to USP 797. Water is not required separately for floor cleaning and a separate disinfecting agent is not required.</td>
</tr>
<tr>
<td>1751.4(e)</td>
<td>Lynn Paulsen</td>
<td>Stated 1754.4 @ hearing; however, that section does not exist.</td>
</tr>
<tr>
<td>1751.4(f)</td>
<td>Douglas Barcon Barcon &amp; Associates</td>
<td>Within the same section of USP 797 that includes numbers (1), (2), and (3) criteria, it also states: “It is incumbent on the compounding personnel to obtain documentation from the manufacturer that the CAI/CACI will meet this standard when located in environments where the background particle counts exceed ISO Class 8 (see Table 1) for 0.5-um and larger particles.” While criteria (1), (2), (3) include “shall” as in the source text of USP 797 in the section on placement of primary engineering controls, the intent in USP 797 is to also include manufacturer documentation that the CAI or CACI will meet criteria (1), (2), (3) in conditions worse than an ISO Class 8 ante-area, i.e., uncontrolled air quality or non-ISO classified room. Note that USP 797 makes no reference to placement of a CAI or CACI in an ISO Class 8 compliant area. It must be inferred that CAI or CACI placement in such area would fall under the same category as air quality worse than ISO Class 8 because it exceeds ISO Class 7. Suggest add (4): (4) manufacturer documentation/certification states that the CAI or CACI is compliant with (1), (2), and (3) of this section when located in environments where the background particle counts exceed ISO Class 8 for 0.5-um and larger particles or is a non-ISO classified area. The addition of “or is a non-ISO classified area” was made because CAI/CACI manufacturers also test their units for compliance in regular room air, which is not tested for ISO compliance but generally is worse than ISO Class 8. Section 1751.4 (h) addresses placement of a CAI in a non-ISO classified room but seems out of sync with the criteria in section 1751.4 (f) and conflicts with it if not changed.</td>
</tr>
<tr>
<td>Code Section</td>
<td>Commenter</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| 1751.4(g)    | Brian Warren  
California Pharmacist  
Association | During the hazardous drug compounding that is performed in a compounding aseptic containment isolator, full hand hygiene and garbing must occur, complete with hair cover, facemask, beard cover (if applicable), polypropylene or low shedding gown that closes in the back, shoe covers, and two layers of gloves with the outermost glove tested to meet ASTM 6978-05. Where the documentation provided by CACI manufacturer does not require garbing, only the two glove requirement shall apply. The proposed regulations require use of a hair cover, beard cover, full gown, and shoe covers. Given the complete isolating nature of compounding within aseptic containment isolators, it is unclear why these garbing requirements are necessary. |
| 1751.4(g)    | BJ Bartleson  
California Hospital Association | Remove the last sentence that states, “where the documentation provided by CACI manufacturer does not require garbing, only the two glove requirement shall apply” CHA believes that a CACI manufacturer should not eliminate the requirement for protective garb and feels this has been confused with CAI requirements. |
| 1751.4(g)    | University  
Compounding  
Pharmacy  
Joe Grasela | Gloves tested to meet ASTM 6978-05 are standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. Why is it necessary to double glove? USP 800 doesn't require or propose a double glove when working with hazardous compounds. During the hazardous drug compounding that is performed in a compounding aseptic containing aseptic containment isolator, full hand hygiene and garbing must occur, complete with hair cover,....and two layers of gloves with the outermost glove tested to meet ASTM 6978-05. |
| 1751.4(i)    | Bruce Lepley  
Community Regional Pharmacy | Reason for Concern: The most recent USP 797 regulations state that viable surface sampling be done periodically. Many hospitals conduct surface sampling every six months to coincide with the requirements for PEC and cleanroom certification. Pharmacies may also not have access to qualified individuals every quarter for surface sampling, but would have access to these qualified individuals every six months for the PEC and cleanroom certifications. Solution: Reduce the viable surface sampling requirement to every six months to coincide with other sampling that will be performed by qualified outside vendors. |
| 1751.4(j)    | Brian Warren  
California Pharmacist  
Association | (j) The pharmacy shall have a comfortable and well-lighted working environment, which includes an appropriate room temperature of 20 degrees Celsius (68 degrees Fahrenheit) or cooler to maintain comfortable conditions for compounding personnel when attired in the required compounding garb. The structure of the working environment standards in Section 1751.4(j) do not contemplate compounding pharmacies using exclusively compounding aseptic isolators and/or compounding aseptic containment isolators. Some of these PECs do not require full garbing. If a compounding pharmacist is not wearing full garbing, the proposed temperature of 20 degrees Celsius may be uncomfortably cold for that pharmacist. We recommend requiring that comfortable conditions be maintained without mandating a specific temperature. |
<p>| 1751.4(j)    | Julie Brosz | (j) The pharmacy shall have a comfortable and well-lighted working environment, which includes a room temperature of 20 degrees Celsius (68 degrees Fahrenheit) or cooler to maintain comfortable conditions for compounding personnel when attired in the required compounding garb. |
| 1751.4(j)    | Anonymous | Since this proposed regulation is intended to address comfort, then it should be a range to accommodate everyone. What is a comfortable temperature is very subjective. Some Californians will find 68 degrees too cold, especially during winter. There is already a regulation defining controlled room temperature. Do we really need another state law to tell us what is comfortable for us? Please let me decide what is comfortable for me. |</p>
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1751.4(j)</td>
<td>Lynn Paulsen</td>
<td>Some Hospitals do not have air conditioners or may keep an area cool, but not at or below 68 degrees. Recommendation is to eliminate temperature or change the wording. The cost to add air conditioning to hospitals would be substantial and would not be offset by patient safety.</td>
</tr>
<tr>
<td>1751.4(j)</td>
<td>BJ Bartleson California Hospital Association</td>
<td>Remove temperature requirement so section will read: “The pharmacy shall have a comfortable and well lighted working environment that maintains comfortable conditions for compounding personnel when attired in the required compounding garb.” Some hospital pharmacies are challenged with precision temperature control, however can continue to maintain a comfortable temperature for employees. The exact temperature stated in this section cannot be supported by evidence and is not required by Cal/OSHA. Therefore, CHA recommends removal of the exact temperature of 68 degrees.</td>
</tr>
<tr>
<td>1751.4(j)</td>
<td>Douglas Barcon Barcon &amp; Associates</td>
<td>The temperature in this section should pertain to the sterile compounding area only per USP. It should not pertain to the whole pharmacy. Cooling the entire pharmacy to 68 degrees Fahrenheit will generally cause staff not garbed for compounding to feel cold and will cause excessive HVAC energy consumption. This may be good to increase profits for PG&amp;E, Southern California Edison, and Sempra Energy, but is not an efficient use of energy.</td>
</tr>
<tr>
<td>1751.5(a)(4)</td>
<td>Julie Brosz</td>
<td>Compounding personnel Sterile Compounding Personnel shall not wear hand, finger, or wrist jewelry. If jewelry cannot be removed then it must be thoroughly cleaned and covered with a sterile glove.</td>
</tr>
<tr>
<td>1751.5(a)(6)</td>
<td>Doug O'Brien Kaiser Permanente</td>
<td>recommending: Change the wording to indicate that only persons with “exposed” rashes, sunburn, weeping sores, etc. and “exposed” cosmetics be excluded from the designated areas. Individuals experiencing with exposed rashes, sunburn, weeping sores, conjunctivitis, active respiratory infections, or those wearing exposed cosmetics shall be excluded from the ISO Class 5 and ISO Class 7 compounding areas until their conditions are remedied. Rationale: The is no risk to patients unless the specified conditions are exposed. Proposed language adds confusion and inhibits compliance and enforcement. The is only a safety risk if the conditions specified are exposed. The rest of section 1751.5 specifies that 100% or nearly 100% of a person’s body is covered with “Personal protective equipment”, from head to toe. The proposed unnecessary provision would cause patient care delays and increase costs that will adversely affect patient access to care. If a NON-exposed condition is discovered after compounding, this proposed regulation provision would cause confusion about what subsequent procedure should be followed. Should the product be recalled despite no risk from a NON-exposed condition? Further, there are serious employee privacy concerns. Should management require a “strip search inspection” before each compounding session to assure that products will not have to be recalled?</td>
</tr>
</tbody>
</table>
Many hospital pharmacy departments are staffed with very few staff members thereby necessitating all staff members, including administrators to be called into action for compounding sterile products.

1. Could the Board specify the cosmetic types or formulations not allowed (shedding of flakes and particles) in ISO Class 5 and ISO Class 7 compounding areas similar to the FDA cosmetic product categories outlined below?

**FDA Product category code = 03 [Eye Makeup Preparations]**
- a. Eyebrow Pencil
- b. Eyeliner
- c. Eye Shadow
- d. Eye Lotion
- e. Eye Makeup Remover
- f. Mascara
- g. Other Eye Makeup Preparations

**FDA Product category code = 07 [Makeup Preparations (not eye)]**
- a. Blushers (all types)
- b. Face Powders
- c. Foundations
- d. Leg and Body Paints
- e. Lipstick
- f. Makeup Bases
- g. Rouges
- h. Makeup Fixatives
- i. Other Makeup Preparations

2. Would the Board allow use of face shields as is used in surgery by operating room nurses for persons wearing cosmetics?

3. Would the Board allow use of cosmetic "sealers" used by professional makeup artists?

"Individuals experiencing active infections, visible rashes or other breaks in exposed skin integrity shall be excluded from the ISO Class 5 and ISO Class 7 compounding areas. Cosmetics, gel nails or nail polish are not allowed. Eyelash extensions are not prohibited.”

CHA suggests new wording in this section to improve specificity and compliance with the regulation.
1751.6. Sterile Compounding Consultation; Training of Sterile Compounding Personnel

(b) The pharmacist-in-charge shall ensure that all pharmacy personnel engaging in compounding sterile drug preparations, Sterile Compounding Personnel have training and demonstrated competence in the safe handling and compounding of sterile drug preparations, including hazardous agents if the pharmacy compounds products with hazardous agents.

(d) The pharmacist-in-charge shall be responsible to ensure the continuing competence of Sterile Compounding Personnel in compounding sterile drug preparations.

(e) Pharmacies that compound sterile drug preparations must comply with the following training requirements:

1. The pharmacy must establish and follow a written program of training and performance evaluation designed to ensure that each person working in the designated area has the knowledge and skills necessary to perform their assigned tasks properly.

2. Aseptic preparation procedures using media-fill tests which are as complicated as the most complex manipulations performed by staff. Sterile Compounding Personnel and which contain the same amount or greater of volume transferred during the selected manipulations.

1751.7(b)

(b) Each individual involved in the preparation of sterile drug preparations, Sterile Compounding Personnel must each first successfully demonstrate competency by successfully performing aseptic media-fill tests before being allowed to prepare sterile drug preparations. The media fill testing process shall be as complicated as the most complex manipulations performed by staff Sterile Compounding Personnel and contain the same amount or greater of volume transferred during the compounding process.

If microbial growth is detected, then the employee’s Sterile Compounding Personnel’s sterile preparation process must be evaluated, corrective action taken and documented, and the media-fill testing repeated. Personnel Sterile Compounding Personnel competency must be revalidated at least every twelve months for sterile to sterile compounding and at least every six months for individuals compounding sterile products from non-sterile ingredients. Aseptic work practice assessments via media fill tests must be revalidated, as appropriate to the circumstance or personnel Sterile Compounding Personnel found to be deficient, whenever the quality assurance program yields an unacceptable result, when the compounding process changes, equipment used in the compounding of sterile drug preparations is replaced, the facility is modified in a manner that affects airflow or traffic patterns, or whenever improper aseptic techniques are observed. Revalidation must be documented.

(c) All sterile compounding personnel must successfully complete an initial competency evaluation. In addition, immediately following the initial hand hygiene and garbing procedure, all compounding personnel Sterile Compounding Personnel must successfully complete a gloved fingertip sampling procedure (zero colony forming units for both hands) at least three times before initially being allowed to compound sterile drug preparations.
1751.7(e) Sterile Compounding Quality Assurance and Process Validation

In a circumstance where a sterile drug preparation compounded from one or more non-sterile ingredients is necessary for immediate dispensing where failure to dispense could result in loss of life or intense suffering,

1. Prior to dispensing:
   a. Notifying the prescriber of the inability to conduct testing;
   b. Suggesting an available alternative product to the prescriber; and
   c. Securing the prescriber’s and patient’s written consent to dispense.

2. And subsequent to dispensing:
   a. Send random sample for sterility and pyrogen testing as part of process validation
   b. Notify physician if results demonstrate microbial growth or pyrogens
   c. Have protocol approved by the Pharmacy & Therapeutics Committee

Would recommend including this section back into the regulation revision to avoid patient loss of life or intense suffering due to the inability to provide emergency medications to patients. In rare circumstances medications such as Alum and Formalin are needed to treat hemorrhagic cystitis that can be life-threatening. Evidence supports that these drugs are needed when other measures fail. The patient could bleed to death without this provision.

Comments: With regards to pyrogen testing, this regulation is in conflict with USP <797>, <85> and <771> recommendations for testing ALL sterile products. USP <797> specifically exempts ophthalmic drops and inhalations from testing for pyrogens. Additionally, USP <85> only provides guidance and limits for pyrogens found in injectable products. There is no defined limit of a pyrogen for a sterile ophthalmic drop or for an inhalation. Without a defined industry standard, it is inappropriate to expect that compounders can comply with this regulation as proposed.

Recommendation: Clarify that pyrogen testing is for sterile INJECTABLE drugs only.

Consider rewording 1751.7 (e):

All non-sterile-to-sterile batch drug preparations shall be subject to documented end product testing for sterility and pyrogens and shall be quarantined until the end product testing confirms sterility. Additionally, non-sterile-to-sterile batch injectable drug preparations shall be subject to documented end product testing for pyrogens and shall be quarantined until the end product testing confirms sterility and acceptable levels of pyrogens, per USP chapter 85 limits, before dispensing. This requirement of end product testing confirming sterility and/or acceptable levels of pyrogens prior to dispensing shall apply regardless of any sterility or pyrogen testing that may have been conducted on any ingredient or combination of ingredients that were previously non-sterile.

References:
USP <797> High Risk Sterile Compounds Sterility Testing and Bacterial Endotoxin (Pyrogen) Testing.
USP <85> Bacterial Endotoxins Testing
USP <771> Ophthalmic Preparations- Quality Tests. This document is consistent with <797> and <85> in that on page 8, Sterility is a quality test required for ALL ophthalmic dosage forms, but Bacterial Endotoxins is required only for injected ophthalmic drug products.
(c)-(e) (1) Batch-produced sterile injectable drug products compounded from one or more non-sterile ingredients. Except as provided in paragraph (2), non-sterile-to-sterile batch drug preparations shall be subject to documented end product testing for sterility and pyrogens and shall be quarantined until the end product testing confirms sterility and acceptable levels of pyrogens, per USP chapter 85 limits, before dispensing. This requirement of end product testing confirming sterility and acceptable levels of pyrogens prior to dispensing shall apply regardless of any sterility or pyrogen testing that may have been conducted on any ingredient or combination of ingredients that were previously non-sterile.

(2) The following non-sterile-to-sterile batch drug preparations do not require end product testing for sterility and pyrogens:
   (A) Preparations for self-administered ophthalmic drops in a quantity sufficient for administration to a single patient for 30 days or less.
   (B) Preparations for self-administered inhalation in a quantity sufficient for administration to a single patient for 30 days or less.
   (C) Preparations compounded in a batch of 25 or fewer doses for a single patient that are terminally sterilized by autoclave or dry heat sterilization.
   (D) Preparations needed for emergency administration to prevent the loss of life or intense suffering, when compounded for administration to a single patient and only in a quantity sufficient for the emergency course of therapy.
   (E) Preparations compounded for a single patient with a chemical stability of 14 days or less.

As stated in the Board’s Initial Statement of Reasons, the justification for changes to this section is to address “the problem of ensuring that board regulations are aligned with compounding standards in USP 37 <797> and reducing such discrepancy for the compounding profession who are compounding drug products in California and shipping into California so as to ensure the safety of all consumers receiving compounded drugs in California.” As currently drafted, the Board’s proposed regulation is not in alignment with USP <797>, and could negatively impact patients due to delays in availability of non-sterile-to-sterile preparations and increases in the cost of non-sterile-to-sterile preparations.

Continued on the next ROW
**1751.7(e)**

**Brian Warren**
California Pharmacist Association

**Continued from previous ROW**

We also acknowledge the Board’s mandate to protect patient safety above all other considerations and understand the intent of adopting standards that are more strict that USP <797>. As such, we recommend establishing a limited number of narrow exceptions to the Board’s end-product testing requirements. The recommended exceptions are consistent with USP <797>.

These narrow exceptions include non-sterile-to-sterile compounds for single-patient, short term ophthalmic products (which is already included by the Board) and inhalation products. Additionally, we propose an exception for small batches compounded for a single patient that are terminally sterilized. Always requiring end-product testing for these preparations will unnecessarily increase costs and harm patient access to these important medications (by about $150 per batch tested).

We also recommend an exception for emergency use. This is particularly important when hospitals experience drug shortages. Absent this exception, it is likely that these preparations will be compounded by non-pharmacists in the hospital setting who have no sterile compounding qualifications. For example, consider the use of LETS (lidocaine, epinephrine, tetracaine, and sodium metabisulfite) solution, commonly used for sterile irrigation and topical anesthesia for lacerations in children. LETS solution should be treated as a non-sterile-to-sterile preparation with terminal sterilization using microfiltration. However, LETS “kits” are also sold in convenient packaging containing all pre-weighed ingredients in their raw, nonsterile forms, which are then compounded in a non-sterile environment using sterile water with or without terminal sterilization. Practices such as this will likely become more common if facilities and providers experience delays in accessing non-sterile-to-sterile preparations from sterile compounding pharmacies. Use of these kits by healthcare personnel other than pharmacists trained in sterile compounding presents a threat to the public health and safety.

Lastly, we recommend an exception for preparations with short-term chemical stability. These preparations will experience chemical degradation prior to completion of end-product testing, which takes 14 days.

**1751.7(f)**

(f) Personnel that are not directly engaged in sterile compounding, but are involved in other compounding activities such as remote checking of compounded products outside the controlled area, do not need to perform practical aseptic preparation tests, but shall otherwise complete all written competency examinations on the process.

Added (f) to clarify that remote checking should not have identical training requirements to actual production of sterile drug preparations in the controlled environment. While written competency tests are appropriate, demonstrations of cleaning and needle handling are not necessary for those personnel not entering the controlled area.

**1751.8**

**Lauren Berton**
CVS Health

It is recommended that the members of the Board review the possibility of removing all language in the 1751.8 a-e and only refer to USP chapter 797 as suggested below. This recommendation is based on reviews and changes to USP chapters on Beyond Use Dating, which would require rewriting of the current rules with every change.

1751.8. Beyond Use Dating for Sterile Compounded Drug Preparations.
In conformity with and in addition to the requirements and limitations of section 1735.2, subdivision (h), every sterile compounded drug preparation shall be given and labeled with a beyond use date that does not exceed the expiration date or beyond use date provided by the manufacturer for any component in the preparation, and that, in the absence of passing a sterility test in accordance with standards for sterility testing found in Chapter 797 of the United States Pharmacopeia – National Formulary (USP37-NF32) Through 2nd Supplement (37th Revision, Effective December 1, 2014), hereby incorporated by reference, that would justify a more extended beyond use date, be labeled with a beyond use date that conforms to the following limitations the storage and beyond use dating guidelines in Chapter 797 of the United States Pharmacopeia – National Formulary (USP37-NF32).
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1751.8       | Douglas Barcon  
Barcon & Associates | Delete “a more” and replace with “an” |
| 1751.8       | Doug O’Brien  
Kaiser Permanente | Recommendation: Add specific language stating that the BUDs defined in sections (a) through (d) may be utilized for preparations compounded in CAIs or CACIs that meet the requirements delineated in 1751.4(f) |
| 1751.8(a)    | Douglas Barcon  
Barcon & Associates | There is no definition for “controlled freezer temperature” in USP 659, USP 797, or general notices in USP-37 NF-32. USP 797 states: “and for 45 days in solid frozen state between -25 degrees and -10 degrees C.” Inconsistent freezer temperatures throughout the freezer can result in some sterile compounded drug preparations or products (premixed piggybacks) being in semi-solid state even though the reported temperature is within range. The key is solid frozen state to qualify for 45-days BUD. Suggest incorporate USP 797 definition including solid frozen state. |
| 1751.8(a)    | University Compounding Pharmacy  
Joe Grasela | …in the absence of passing a sterility test …  
(a) The beyond use date shall specify that the storage and exposure periods cannot exceed 48 hours at controlled room temperature, 14 days at controlled cold temperature, and 45 days at controlled freezer temperature…(1) The preparation is compounded entirely within an ISP Class 5 PEC located in an ISO Class 7 buffer area or cleanroom…using only sterile ingredients, products, components, and devices,…(2) …using not more than 3 commercially manufactured packages of sterile preparations and not more than two entries into any one sterile container…  
(b) The beyond use date shall specify that storage and exposure periods cannot exceed 30 hours at controlled room temperature, 9 days at controlled cold temperature, and 45 days at controlled freezer temperature, there the sterile compounded drug preparation is compounded solely with aseptic manipulations and all of the following apply: (1) The preparation is compounded entirely within an ISO Class 5 PEC located in an ISO Class 7 buffer area or cleanroom….a compounded sterile preparation that will be administered either to multiple patients or to one patient on multiple occasions…(2) The compounding process involves complex manipulations other than the single-volume transfer…  
Section (b) is clearly defines the end user and applicable to multiple patients or to one patient using a multi-use container however section (a) does not define it's end user. Is section (a) also applicable to multiple patients or multi-use container as well?  
Section (b) is only applicable if using more than 3 commercially manufactured packages. Is that the only difference? Therefore why wouldn't section (a) be applicable for multiple users or multi-use container? |
| 1751.8(a)(1) | Michael Tou  
Providence Health | (1) The preparation is compounded entirely within an ISO Class 5 PEC in an ISO Class 7 buffer area or cleanroom with an ante-area, or better air quality…  
The proposed language restricts sterile compounding with USP 797 defined beyond-use dating to only within an ISO 7 buffer area with an ante-area. USP 797 guidelines allow for sterile compounding within a CAI or CACI that meets all of the operational criteria as defined in Section 1751.4(f) and use of beyond-use dating specified. A buffer area and ante-area should not be required. Providence recommends adopting the wording used in USP 797. |
| 1751.8(b)    | Douglas Barcon  
Barcon & Associates | There is no definition for “controlled freezer temperature” in USP 659, USP 797, or general notices in USP-37 NF-32. USP 797 states: “and for 45 days in solid frozen state between -25 degrees and -10 degrees C.” Inconsistent freezer temperatures throughout the freezer can result in some sterile compounded drug preparations or products (premixed piggybacks) being in semi-solid state even though the reported temperature is within range. The key is solid frozen state to qualify for 45-days BUD. Suggest incorporate USP 797 definition including solid frozen state. |
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1751.8(b)(1) | Michael Tou Providence Health | (1) The preparation is compounded entirely within an ISO Class 5 PEC located in an ISO Class 7 buffer area or cleanroom with an ante-area, or better air quality...

The proposed language restricts sterile compounding with USP 797 defined beyond-use dating to only within an ISO 7 buffer area with an ante-area. USP 797 guidelines allow for sterile compounding within a CAI or CACI that meets all of the operational criteria as defined in Section 1751.4(f) and use of beyond-use dating specified. A buffer area and ante-area should not be required.

Providence recommends adopting the wording used in USP 797. |
| 1751.8(c) | Douglas Barcon Barcon & Associates | There is no definition for “controlled freezer temperature” in USP 659, USP 797, or general notices in USP-37 NF-32. USP 797 states: “and for 45 days in solid frozen state between -25 degrees and -10 degrees C.” Inconsistent freezer temperatures throughout the freezer can result in some sterile compounded drug preparations or products (premixed piggybacks) being in semi-solid state even though the reported temperature is within range. The key is solid frozen state to qualify for 45-days BUD. Suggest incorporate USP 797 definition including solid frozen state. |
| 1751.8(c) | William Stuart Hartley Medical | Recommend:

The beyond use date shall specify that storage and exposure periods cannot exceed 24 hours at controlled room temperature, 3 days at controlled cold temperature, and 45 days at controlled freezer temperature, where the sterile compounded drug preparation is compounded solely with aseptic manipulations using non-sterile ingredients, including manufactured preparations not intended for sterile routes of administration, or non-sterile devices, before terminal sterilization, or where the sterile compounded drug preparation lacks effective antimicrobial preservatives.

Rationale:

The clause, “or where the sterile compounded drug preparation lacks effective antimicrobial preservatives” is not referenced in USP <797>.

Numerous CSP’s prepared do not contain antimicrobial preservatives, such as: Total Parenteral Nutrition, Large and Small Volume Parenterals, Antibiotics, and Morphine Infusions utilized in home care setting that are currently categorized as Low and Medium Risk preparations.

Antimicrobial preservatives are contra-indicated in epidural / intrathecal infusions. Therefore, Morphine (Infumorph) and bupivacaine (Marcaine), which are currently categorized as Low Risk with a 14-day BUD, would change to 72 hours under proposed regulations.

Certain compounded preparations have inherent antimicrobial properties. The active pharmaceutical ingredient, osmotic forces, base vehicle, and pH can contribute to decreased microbial survivability.

<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
</table>
| 1751.8(e)(1) | Bruce Lepley  
Community Regional Pharmacy | Reason for Concern: Many large health care facilities already employ the use of an “immediate use only” label for reasons other than a 1 hour BUD (e.g. criticality of the drug, cost of the drug, etc.)  
In addition, other regulatory agencies (i.e. The Joint Commission) have stipulations in existence for labeling “immediate use” sterile products (i.e. medication name, strength, quantity, diluent and volume, expiration date when not used within 24 hours, and expiration time when expiration occurs in less than 24 hours). To avoid confusion, it would be beneficial to specifically remove the requirement of labeling the product for “immediate use only” and impose the existing regulation of the expiration time when expiration occurs in less than 24 hours. |
|              |           | Solution: Replace the requirement of labeling for “immediate use only” with the exact one hour beyond use date and time. |
|              |           | Reason for Concern: This section does not stipulate as to whether this applies to all healthcare professionals who are qualified to engage in immediate use sterile compounding drug preparation outside the profession of pharmacy. |
|              |           | Solution: Please clarify and insert verbiage to make clear of whether or not this stipulation applies to all professions outside of pharmacy who are qualified to engage in immediate use sterile compounding (e.g. RN). |
| 1751.8(e)(2) | Bruce Lepley  
Community Regional Pharmacy | Reason for Concern: Other regulatory agencies (i.e. The Joint Commission) have stipulations in existence for one to compound immediate use sterile products which include: “…a delay could harm the patient …or the products stability is short. To mitigate risk of confusion we recommend adopting similar language that would accomplish the intent of this section. |
|              |           | Solution: Reword section to use “a delay could harm the patient” or “the products stability is short”. |
| 1751.9(a), (b), (c) | Doug O’Brien  
Kaiser Permanente | Recommendation: Include above language from USP 797 allowing the use of proven technologies with quality assurance procedures (for example, Closed System Transfer Devices) allowing for extension of BUD for single-dose vials. |
<p>|              |           | Rationale: One of the hallmarks of USP and Current Good Manufacturing Practices (cGMP) is the ability of entities under the guidelines to be innovative and advance practice with validated processes that differ from the current standards. The advancement of knowledge, technology, and validation processes in a very fluid environment must be allowed to flourish; thus the ability to design programs that meet or exceed current outcomes is essential. The key statement allowing this within the USP 797 is as follows: “The use of technologies, techniques, materials, and procedures other than those described in this chapter is not prohibited so long as they have been proven to be equivalent or superior with statistical significance to those described herein.” |
|              |           | The regulation as proposed is confusing to industry professionals and the Board of Pharmacy’s intent. |
|              |           | The recommendation aids in concordance with USP Chapter 797 National Standards and aids in reduction in drug wastage, increases opportunities to save drug during manufacturer shortages and may result in significant health care cost savings. |</p>
<table>
<thead>
<tr>
<th>Code Section</th>
<th>Commenter</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1751.9(b)</td>
<td>Katherine Palmer Rita Shane Cedars-Sinai Medical Center</td>
<td>Unless otherwise specified by the manufacturer, a multi-dose container stored according to the manufacturer’s specifications shall be used in its entirety or its remaining contents discarded within twenty eight (28) days from initial opening or puncture. Any multi-dose container not stored according to the manufacturer’s specifications shall be discarded immediately upon identification of such storage circumstance. (4) The use of technologies, techniques, materials, and procedures other than those described in this sterile compounding section is not prohibited so long as they have been proven to be equivalent or superior with statistical significance to those described herein” (USP 797 page 1). Additionally, as a result, counterfeit chemotherapy is an area of national concern, until such time as E-Pedigree is available. Closed system transfer devices (CTSD) protect the vial from entry of external bacteria after initial puncture beyond the USP 797 approved 6 hour time limit. It has been shown that one of these systems maintains sterility of the vials to which it is attached for up to 168 hours (7 days). Recommendation: Allowance to use CTSDs with supporting literature to extend the beyond use date of single dose vials of chemotherapy to 24 hours or use through the end of the shift, whichever is shorter. This recommendation is more conservative than the timeframe of 7 days listed in the CTSD study and would assist institutions in conserving scarce chemotherapy medications.</td>
</tr>
</tbody>
</table>

| General Comment | University Compounding Pharmacy Joe Grasela | Just a suggestion. If we go with USP 797 and 795 and 71 and 800 I think all the work is done for you. its reviewed by the usp and sent out to all states BOP’S and people involved for review. Also our inspection for a sterile license would satisfy other states that require 797 compliance. |

| General Comment | Michael Tou Providence Health | We urge the board to clarify the intent of the rule language in section 1735.2(d)(3) and 1751.2(b). The board committed to preparing guidance rather than amend the language for these two sections in response to our comments during previous rulemaking. |

| General Comment | Katherine Palmer Rita Shane Cedars-Sinai Medical Center | 1) Ability to provide emergency therapy to patients to avoid patient loss of life or intense suffering when other hemorrhagic cystitis treatments have failed. 2) Ability to provide chemotherapy to patients in the setting of continued drug shortages of cancer medications by using equivalent or superior technologies for preserving medication vials. |